1
|
Weber WP, Shaw J, Pusic A, Wyld L, Morrow M, King T, Mátrai Z, Heil J, Fitzal F, Potter S, Rubio IT, Cardoso MJ, Gentilini OD, Galimberti V, Sacchini V, Rutgers EJT, Benson J, Allweis TM, Haug M, Paulinelli RR, Kovacs T, Harder Y, Gulluoglu BM, Gonzalez E, Faridi A, Elder E, Dubsky P, Blohmer JU, Bjelic-Radisic V, Barry M, Hay SD, Bowles K, French J, Reitsamer R, Koller R, Schrenk P, Kauer-Dorner D, Biazus J, Brenelli F, Letzkus J, Saccilotto R, Joukainen S, Kauhanen S, Karhunen-Enckell U, Hoffmann J, Kneser U, Kühn T, Kontos M, Tampaki EC, Carmon M, Hadar T, Catanuto G, Garcia-Etienne CA, Koppert L, Gouveia PF, Lagergren J, Svensjö T, Maggi N, Kappos EA, Schwab FD, Castrezana L, Steffens D, Krol J, Tausch C, Günthert A, Knauer M, Katapodi MC, Bucher S, Hauser N, Kurzeder C, Mucklow R, Tsoutsou PG, Sezer A, Çakmak GK, Karanlik H, Fairbrother P, Romics L, Montagna G, Urban C, Walker M, Formenti SC, Gruber G, Zimmermann F, Zwahlen DR, Kuemmel S, El-Tamer M, Vrancken Peeters MJ, Kaidar-Person O, Gnant M, Poortmans P, de Boniface J. Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy. Breast 2022; 63:123-139. [PMID: 35366506 PMCID: PMC8976143 DOI: 10.1016/j.breast.2022.03.008] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 03/03/2022] [Accepted: 03/14/2022] [Indexed: 12/31/2022] Open
Abstract
Aim Demand for nipple- and skin- sparing mastectomy (NSM/SSM) with immediate breast reconstruction (BR) has increased at the same time as indications for post-mastectomy radiation therapy (PMRT) have broadened. The aim of the Oncoplastic Breast Consortium initiative was to address relevant questions arising with this clinically challenging scenario. Methods A large global panel of oncologic, oncoplastic and reconstructive breast surgeons, patient advocates and radiation oncologists developed recommendations for clinical practice in an iterative process based on the principles of Delphi methodology. Results The panel agreed that surgical technique for NSM/SSM should not be formally modified when PMRT is planned with preference for autologous over implant-based BR due to lower risk of long-term complications and support for immediate and delayed-immediate reconstructive approaches. Nevertheless, it was strongly believed that PMRT is not an absolute contraindication for implant-based or other types of BR, but no specific recommendations regarding implant positioning, use of mesh or timing were made due to absence of high-quality evidence. The panel endorsed use of patient-reported outcomes in clinical practice. It was acknowledged that the shape and size of reconstructed breasts can hinder radiotherapy planning and attention to details of PMRT techniques is important in determining aesthetic outcomes after immediate BR. Conclusions The panel endorsed the need for prospective, ideally randomised phase III studies and for surgical and radiation oncology teams to work together for determination of optimal sequencing and techniques for PMRT for each patient in the context of BR Autologous breast reconstruction is increasingly preferred over implants in the setting of radiation therapy. Use of patient-reported outcomes is endorsed. Shape and size of reconstructed breasts can hinder radiotherapy planning. There is a need for randomised phase III trials.
Collapse
Affiliation(s)
- Walter Paul Weber
- Breast Center, University Hospital Basel, Basel, Switzerland; University of Basel, Basel, Switzerland.
| | - Jane Shaw
- Patient Advocacy Group, Oncoplastic Breast Consortium, Basel, Switzerland
| | - Andrea Pusic
- Brigham and Women's/Dana Farber Cancer Center, USA
| | - Lynda Wyld
- Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
| | - Monica Morrow
- Breast Surgery Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Tari King
- Department of Surgery, Brigham and Women's Hospital / Dana Farber Cancer Institute, USA
| | - Zoltán Mátrai
- Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, Hungary
| | - Jörg Heil
- Department of Obstetrics and Gynecology, University of Heidelberg, Medical School, Heidelberg, Germany
| | - Florian Fitzal
- Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Shelley Potter
- Bristol Centre for Surgical Research, Bristol Medical School, University of Bristol, Clifton, Bristol, UK
| | - Isabel T Rubio
- Breast Surgical Oncology, Clinica Universidad de Navarra, Madrid, Spain
| | - Maria-Joao Cardoso
- Breast Unit, Champalimaud Clinical Centre, Champalimaud Foundation, And Nova Medical School, Lisbon, Portugal
| | | | | | - Virgilio Sacchini
- Breast Surgery Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Emiel J T Rutgers
- Department of Surgery, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands
| | - John Benson
- Cambridge Breast Unit, Addenbrooke's Hospital Cambridge, Cambridge, UK; Cambridge Breast Unit, Cambridge University Hospitals NHS Foundation TRUST, School of Medicine, Anglia Ruskin University, Cambridge, UK
| | - Tanir M Allweis
- Hadassah Medical Center & Faculty of Medicine, Hebrew University, Jerusalem, Israel
| | - Martin Haug
- Breast Center and Department of Plastic, Reconstructive, Aesthetic and Handsurgery University Hospital Basel, University of Basel, Basel, Switzerland
| | - Regis R Paulinelli
- Federal University of Goiás, Araújo Jorge Hospital, Goiás Anti-Cancer Association, Goiás, Brazil
| | - Tibor Kovacs
- Jiahui Internatioonal Hospital Shanghai, China; Guy's and St. Thomas' NHS Foundation Trust London, UK
| | - Yves Harder
- Department of Plastic, Reconstructive and Aesthetic Surgery, Ospedale Regionale di Lugano, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland; Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland
| | | | - Eduardo Gonzalez
- Departament of Mastology, Breast Unit- Instituto de Oncología Angel H Roffo, Buenos Aires Univesity. Buenos Aires, Argentina
| | - Andree Faridi
- Department of Senology/Breast Center, University Hospital Bonn, Germany
| | - Elisabeth Elder
- Westmead Breast Cancer Institute, Westmead Hospital, University of Sydney, Australia
| | - Peter Dubsky
- Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Breast Center, Hirslanden Clinic St. Anna, Lucerne, Switzerland
| | - Jens-Uwe Blohmer
- Department of Gynecology and Breast Center, Charité University Hospital, Berlin, Germany
| | - Vesna Bjelic-Radisic
- Breast Unit, Helios University Hospital, University Witten/Herdecke, Wuppertal, Germany
| | - Mitchel Barry
- Mater Misericordiae University Hospital, Dublin, Ireland
| | - Susanne Dieroff Hay
- Patient Advocacy Group, Oncoplastic Breast Consortium, President, the Swedish Breast Cancer Association, Stockholm, Sweden
| | - Kimberly Bowles
- Patient Advocacy Group, Oncoplastic Breast Consortium, Not Putting on A Shirt, Pittsburgh, USA
| | - James French
- Westmead Breast Cancer Institute, Westmead Hospital, University of Sydney, Australia
| | - Roland Reitsamer
- Breast Center Salzburg, University Clinic Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria
| | - Rupert Koller
- Department of Plastic, Aesthetic and Reconstructive Surgery, Vienna Health Services, Clinic Landstrasse and Clinic Ottakring, Vienna, Austria
| | - Peter Schrenk
- Breast Cancer Center, Kepler University Hospital, Linz, Austria
| | | | - Jorge Biazus
- Division of Breast Surgery, Universidade Federal Do Rio Grande Do Sul (UFRGS), Porto Alegre, Brazil
| | - Fabricio Brenelli
- Breast Oncology Division, University of Campinas, Campinas, São Paulo, Brazil
| | - Jaime Letzkus
- San Borja Arriaran Clinical Hospital, University of Chile, Chile
| | | | | | - Susanna Kauhanen
- Department of Plastic Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
| | - Ulla Karhunen-Enckell
- Tampere University Hospital, Department of Surgery and Tays Cancer Center, Tampere, Finland
| | - Juergen Hoffmann
- Breast Center, University Hospital Düsseldorf, Düsseldorf, Germany
| | - Ulrich Kneser
- Department of Hand, Plastic and Reconstructive Surgery - Burn Center, BG Trauma Center Ludwigshafen/Rhine, Hand and Plastic Surgery, University Heidelberg, Heidelberg, Germany
| | - Thorsten Kühn
- Interdisciplinary Breast Center, Klinikum Esslingen, Germany
| | | | - Ekaterini Christina Tampaki
- Department of Plastic, Reconstructive Surgeryand Burn Unit, KAT Athens Hospital and Trauma Center, Athens, Greece
| | | | - Tal Hadar
- Hadassah Medical Center & Faculty of Medicine, Hebrew University, Jerusalem, Israel
| | - Giuseppe Catanuto
- Multidisciplinary Breast Unit, Azienda Ospedaliera Cannizzaro, Catania, Italy
| | | | - Linetta Koppert
- Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
| | - Pedro F Gouveia
- Breast Unit, Champalimaud Clinical Centre, Champalimaud Foundation, And Nova Medical School, Lisbon, Portugal
| | - Jakob Lagergren
- Department of Surgery, Capio St Goran's Hospital, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
| | - Tor Svensjö
- Department of Surgery, Central Hospital, Kristianstad, Sweden
| | - Nadia Maggi
- Breast Center, University Hospital Basel, Basel, Switzerland
| | - Elisabeth A Kappos
- Breast Center and Department of Plastic, Reconstructive, Aesthetic and Handsurgery University Hospital Basel, University of Basel, Basel, Switzerland
| | | | | | - Daniel Steffens
- Breast Center, University Hospital Basel, Basel, Switzerland
| | - Janna Krol
- Breast Center, University Hospital Basel, Basel, Switzerland
| | | | | | - Michael Knauer
- Breast Center Eastern Switzerland, St. Gallen, Switzerland
| | - Maria C Katapodi
- University of Basel, Basel, Switzerland; Patient Advocacy Group, Oncoplastic Breast Consortium, Basel, Switzerland
| | - Susanne Bucher
- Breast Center, Lucerne Cantonal Hospital, Lucerne, Switzerland
| | - Nik Hauser
- Breast Center, Hirslanden Clinic Aarau, Aarau, Frauenarztzentrum Aargau AG, Baden, Switzerland
| | - Christian Kurzeder
- Breast Center, University Hospital Basel, Basel, Switzerland; University of Basel, Basel, Switzerland
| | - Rosine Mucklow
- Patient Advocacy Group, Oncoplastic Breast Consortium, Basel, Switzerland
| | - Pelagia G Tsoutsou
- University Hospital Geneva, University of Geneva, Faculty of Medicine, Geneva, Switzerland
| | - Atakan Sezer
- Department of Surgery, Trakya University Medical School Hospital, Turkey
| | - Güldeniz Karadeniz Çakmak
- Department of Surgery, The School of Medicine, Zonguldak Bulent Ecevit University, Zonguldak, Turkey
| | | | - Patricia Fairbrother
- Patient Advocacy Group, Oncoplastic Breast Consortium, Breakthrough Breast Cancer, Association Breast Surgery UKBCC, Kedleston, UK
| | - Laszlo Romics
- Department of Surgery, New Victoria Hospital, Glasgow, UK
| | - Giacomo Montagna
- Breast Surgery Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Cicero Urban
- Breast Unit, Hospital Nossa Senhora Das Graças, Curitiba, Brazil
| | - Melanie Walker
- Breast Endocrine and General Surgery Unit, The Alfred, Melbourne, Australia; Breast Surgeons of Australia and New Zealand (BreastSurgANZ), Australia
| | - Silvia C Formenti
- Department of Radiation Oncology and Meyer Cancer Center, Weill Cornell Medicine, USA
| | - Guenther Gruber
- Institute for Radiotherapy, Klinik Hirslanden, 8032, Zurich, Switzerland; University of Berne, 3000, Bern, Switzerland
| | - Frank Zimmermann
- Clinic of Radiation Oncology, University Hospital Basel, Basel, Switzerland
| | - Daniel Rudolf Zwahlen
- Department of Radiation Oncology, Cantonal Hospital of Winterthur, Winterthur, Switzerland
| | - Sherko Kuemmel
- Department of Gynecology and Breast Center, Charité University Hospital, Berlin, Germany; Breast Unit, Kliniken Essen-Mitte, Germany
| | - Mahmoud El-Tamer
- Breast Surgery Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Marie Jeanne Vrancken Peeters
- Department of Surgical Oncology Netherlands Cancer Institute, Antoni van Leeuwenhoek & Amsterdam University Medical Center, Netherlands
| | - Orit Kaidar-Person
- Breast Radiation Therapy Unit, Sheba Tel Hashomer, Ramat Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Michael Gnant
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Philip Poortmans
- Iridium Netwerk and University of Antwerp, Wilrijk-Antwerpen, Belgium
| | - Jana de Boniface
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Surgery, Capio St Göran's Hospital, Stockholm, Sweden
| |
Collapse
|
2
|
Fitzal F, Bolliger M, Dunkler D, Geroldinger A, Gambone L, Heil J, Riedel F, de Boniface J, Andre C, Matrai Z, Pukancsik D, Paulinelli RR, Ostapenko V, Burneckis A, Ostapenko A, Ostapenko E, Meani F, Harder Y, Bonollo M, Alberti ASM, Tausch C, Papassotiropoulos B, Helfgott R, Heck D, Fehrer HJ, Acko M, Schrenk P, Trapp E, Gunda P, Clara P, Montagna G, Ritter M, Blohmer JU, Steffen S, Romics L, Morrow E, Lorenz K, Fehr M, Weber WP. ASO Visual Abstract: Retrospective Multicenter Analysis Comparing Conventional with Oncoplastic Breast-Conserving Surgery: Oncological and Surgical Outcomes in Women with High-Risk Breast Cancer from the OPBC-01/iTOP2 Study. Ann Surg Oncol 2021. [PMID: 34676460 DOI: 10.1245/s10434-021-10898-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Affiliation(s)
- Florian Fitzal
- Department of General Surgery and Breast Health Center, Medical University Vienna, Vienna, Austria.
| | - Michael Bolliger
- Department of General Surgery and Breast Health Center, Medical University Vienna, Vienna, Austria
| | - Daniela Dunkler
- Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria
| | - Angelika Geroldinger
- Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria
| | - Luca Gambone
- Department of General Surgery and Breast Health Center, Medical University Vienna, Vienna, Austria
| | - Jörg Heil
- Departement of Obstetrics and Gynecology, Breast Center, Heidelberg University Hospital, Heidelberg, Germany
| | - Fabian Riedel
- Departement of Obstetrics and Gynecology, Breast Center, Heidelberg University Hospital, Heidelberg, Germany
| | - Jana de Boniface
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.,Departemt of Surgery, Capio S:t Göran's Hospital, Stockholm, Sweden
| | - Camilla Andre
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.,Department of Surgery, Uppsala University Hospital, Uppsala, Sweden
| | - Zoltan Matrai
- Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, Hungary
| | - Dávid Pukancsik
- Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, Hungary
| | - Regis R Paulinelli
- Araújo Jorge Hospital, Federal University of Goiás, Goiás Anti-Cancer Association, Goiás, Brazil
| | - Valerijus Ostapenko
- National Cancer Institute Vilnius Lithuania, Vilnius, Lithuania.,Faculty of Medicine, University of Vilnius, Vilnius, Lithuania
| | - Arvydas Burneckis
- National Cancer Institute Vilnius Lithuania, Vilnius, Lithuania.,Faculty of Medicine, University of Vilnius, Vilnius, Lithuania
| | - Andrej Ostapenko
- National Cancer Institute Vilnius Lithuania, Vilnius, Lithuania.,Faculty of Medicine, University of Vilnius, Vilnius, Lithuania
| | - Edvin Ostapenko
- National Cancer Institute Vilnius Lithuania, Vilnius, Lithuania.,Faculty of Medicine, University of Vilnius, Vilnius, Lithuania
| | - Francesco Meani
- Centro di Senologia della Svizzera Italiana (CSSI), Lugano, Switzerland.,Department of Obstetrics and Gynecology, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland
| | - Yves Harder
- Centro di Senologia della Svizzera Italiana (CSSI), Lugano, Switzerland.,Department of Plastic, Reconstructive and Aesthetic Surgery, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.,Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland
| | - Marta Bonollo
- Centro di Senologia della Svizzera Italiana (CSSI), Lugano, Switzerland.,Department of Obstetrics and Gynecology, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland
| | - Andrea S M Alberti
- Centro di Senologia della Svizzera Italiana (CSSI), Lugano, Switzerland.,Department of Plastic, Reconstructive and Aesthetic Surgery, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.,Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland
| | | | | | - Ruth Helfgott
- Department of Surgery, Ordensklinikum Linz - Sisters of Charity, Linz, Austria
| | - Dietmar Heck
- Department of Surgery, Ordensklinikum Linz - Sisters of Charity, Linz, Austria
| | - Hans-Jörg Fehrer
- Department of Surgery, Ordensklinikum Linz - Sisters of Charity, Linz, Austria
| | - Markus Acko
- Department of Surgery, Ordensklinikum Linz - Sisters of Charity, Linz, Austria
| | - Peter Schrenk
- Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria
| | - Elisabeth Trapp
- Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria
| | - Pristauz Gunda
- Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria
| | - Paliczek Clara
- Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria
| | - Giacomo Montagna
- Breast Center, University Hospital of Basel, Basel, Switzerland.,Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Mathilde Ritter
- Breast Center, University Hospital of Basel, Basel, Switzerland
| | - Jens-Uwe Blohmer
- Department of Gynecology and Breast Center, Charité University Hospital Campus Charité-Mitte, Berlin, Germany
| | - Sander Steffen
- Clinical Cancer Registry, Charité Comprehensive Cancer Center (CCCC), University Medical Center Berlin, Campus Charité Mitte, Berlin, Germany
| | - Laszlo Romics
- New Victoria Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK
| | - Elizabeth Morrow
- Department of Academic Surgery, University of Glasgow, Glasgow, UK
| | - Katharina Lorenz
- Department of Gynecology and Obstetrics, Cantonal Hospital, Frauenfeld, Frauenfeld, Switzerland
| | - Mathias Fehr
- Department of Gynecology and Obstetrics, Cantonal Hospital, Frauenfeld, Frauenfeld, Switzerland
| | - Walter Paul Weber
- Breast Center, University Hospital of Basel, Basel, Switzerland.,University of Basel, Basel, Switzerland
| |
Collapse
|
3
|
Fitzal F, Bolliger M, Dunkler D, Geroldinger A, Gambone L, Heil J, Riedel F, de Boniface J, Andre C, Matrai Z, Pukancsik D, Paulinelli RR, Ostapenko V, Burneckis A, Ostapenko A, Ostapenko E, Meani F, Harder Y, Bonollo M, Alberti ASM, Tausch C, Papassotiropoulos B, Helfgott R, Heck D, Fehrer HJ, Acko M, Schrenk P, Trapp EK, Gunda PT, Clara P, Montagna G, Ritter M, Blohmer JU, Steffen S, Romics L, Morrow E, Lorenz K, Fehr M, Weber WP. Retrospective, Multicenter Analysis Comparing Conventional with Oncoplastic Breast Conserving Surgery: Oncological and Surgical Outcomes in Women with High-Risk Breast Cancer from the OPBC-01/iTOP2 Study. Ann Surg Oncol 2021; 29:1061-1070. [PMID: 34647202 PMCID: PMC8724061 DOI: 10.1245/s10434-021-10809-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Accepted: 09/03/2021] [Indexed: 11/18/2022]
Abstract
Introduction Recent data suggest that margins ≥2 mm after breast-conserving surgery may improve local control in invasive breast cancer (BC). By allowing large resection volumes, oncoplastic breast-conserving surgery (OBCII; Clough level II/Tübingen 5-6) may achieve better local control than conventional breast conserving surgery (BCS; Tübingen 1-2) or oncoplastic breast conservation with low resection volumes (OBCI; Clough level I/Tübingen 3-4). Methods Data from consecutive high-risk BC patients treated in 15 centers from the Oncoplastic Breast Consortium (OPBC) network, between January 2010 and December 2013, were retrospectively reviewed. Results A total of 3,177 women were included, 30% of whom were treated with OBC (OBCI n = 663; OBCII n = 297). The BCS/OBCI group had significantly smaller tumors and smaller resection margins compared with OBCII (pT1: 50% vs. 37%, p = 0.002; proportion with margin <1 mm: 17% vs. 6%, p < 0.001). There were significantly more re-excisions due to R1 (“ink on tumor”) in the BCS/OBCI compared with the OBCII group (11% vs. 7%, p = 0.049). Univariate and multivariable regression analysis adjusted for tumor biology, tumor size, radiotherapy, and systemic treatment demonstrated no differences in local, regional, or distant recurrence-free or overall survival between the two groups. Conclusions Large resection volumes in oncoplastic surgery increases the distance from cancer cells to the margin of the specimen and reduces reexcision rates significantly. With OBCII larger tumors are resected with similar local, regional and distant recurrence-free as well as overall survival rates as BCS/OBCI. Supplementary information The online version contains supplementary material available at 10.1245/s10434-021-10809-1.
Collapse
Affiliation(s)
- Florian Fitzal
- Department of General Surgery and Breast Health Center, Medical University Vienna, Vienna, Austria.
| | - Michael Bolliger
- Department of General Surgery and Breast Health Center, Medical University Vienna, Vienna, Austria
| | - Daniela Dunkler
- Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria
| | - Angelika Geroldinger
- Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria
| | - Luca Gambone
- Department of General Surgery and Breast Health Center, Medical University Vienna, Vienna, Austria
| | - Jörg Heil
- Departement of Obstetrics and Gynecology, Breast Center, Heidelberg University Hospital, Heidelberg, Germany
| | - Fabian Riedel
- Departement of Obstetrics and Gynecology, Breast Center, Heidelberg University Hospital, Heidelberg, Germany
| | - Jana de Boniface
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.,Departemt of Surgery, Capio St Göran's Hospital, Stockholm, Sweden
| | - Camilla Andre
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.,Department of Surgery, Uppsala University Hospital, Uppsala, Sweden
| | - Zoltan Matrai
- Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, Hungary
| | - Dávid Pukancsik
- Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, Hungary
| | - Regis R Paulinelli
- Federal University of Goiás, Araújo Jorge Hospital, Goiás Anti-Cancer Association, Goiás, Brazil
| | - Valerijus Ostapenko
- National Cancer Institute Vilnius Lithuania, Vilnius, Lithuania.,Faculty of Medicine, University of Vilnius, Vilnius, Lithuania
| | - Arvydas Burneckis
- National Cancer Institute Vilnius Lithuania, Vilnius, Lithuania.,Faculty of Medicine, University of Vilnius, Vilnius, Lithuania
| | - Andrej Ostapenko
- National Cancer Institute Vilnius Lithuania, Vilnius, Lithuania.,Faculty of Medicine, University of Vilnius, Vilnius, Lithuania
| | - Edvin Ostapenko
- National Cancer Institute Vilnius Lithuania, Vilnius, Lithuania.,Faculty of Medicine, University of Vilnius, Vilnius, Lithuania
| | - Francesco Meani
- Centro di Senologia della Svizzera Italiana (CSSI), Lugano, Switzerland.,Department of Obstetrics and Gynecology, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland
| | - Yves Harder
- Centro di Senologia della Svizzera Italiana (CSSI), Lugano, Switzerland.,Department of Plastic, Reconstructive and Aesthetic Surgery, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.,Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland
| | - Marta Bonollo
- Centro di Senologia della Svizzera Italiana (CSSI), Lugano, Switzerland.,Department of Obstetrics and Gynecology, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland
| | - Andrea S M Alberti
- Centro di Senologia della Svizzera Italiana (CSSI), Lugano, Switzerland.,Department of Plastic, Reconstructive and Aesthetic Surgery, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.,Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland
| | | | | | - Ruth Helfgott
- Department of Surgery, Ordensklinikum Linz - Sisters of Charity, Linz, Austria
| | - Dietmar Heck
- Department of Surgery, Ordensklinikum Linz - Sisters of Charity, Linz, Austria
| | - Hans-Jörg Fehrer
- Department of Surgery, Ordensklinikum Linz - Sisters of Charity, Linz, Austria
| | - Markus Acko
- Department of Surgery, Ordensklinikum Linz - Sisters of Charity, Linz, Austria
| | - Peter Schrenk
- Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria
| | - Elisabeth K Trapp
- Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria
| | | | - Paliczek Clara
- Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria
| | - Giacomo Montagna
- Breast Center, University Hospital of Basel, Basel, Switzerland.,Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Mathilde Ritter
- Breast Center, University Hospital of Basel, Basel, Switzerland
| | - Jens-Uwe Blohmer
- Department of Gynecology and Breast Center, Charité University Hospital Campus Charité-Mitte, Berlin, Germany
| | - Sander Steffen
- Clinical Cancer Registry, Charité Comprehensive Cancer Center (CCCC), University Medical Center Berlin, Campus Charité Mitte, Berlin, Germany
| | - Laszlo Romics
- New Victoria Hospital, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
| | - Elizabeth Morrow
- Department of Academic Surgery, University of Glasgow, Glasgow, United Kingdom
| | - Katharina Lorenz
- Department of Gynecology and Obstetrics, Cantonal Hospital Frauenfeld, Frauenfeld, Switzerland
| | - Mathias Fehr
- Department of Gynecology and Obstetrics, Cantonal Hospital Frauenfeld, Frauenfeld, Switzerland
| | - Walter Paul Weber
- Breast Center, University Hospital of Basel, Basel, Switzerland.,University of Basel, Basel, Switzerland
| |
Collapse
|
4
|
Fitzal F, Bolliger M, Dunkler D, Gambone L, Heil J, Riedel F, de Boniface J, André C, Matrai Z, Pukancsik D, Paulinelli R, Ostapenko V, Burneckis A, Ostapenko A, Ostapenko E, Meani F, Harder Y, Bonollo M, Alberti A, Tausch C, Papassotiropoulos B, Helfgott R, Heck D, Fehrer H, Acko M, Schrenk P, Montagna G, Trapp E, Pristauz G, Paliczek C, Blohmer J, Steffen S, Romics L, Morrow E, Lorenz K, Fehr M, Ritter M, Weber W. Retrospective multicenter analysis comparing conventional with oncoplastic breast conservation: oncologic and surgical outcome in women with high risk breast cancer from the OPBC-01/iTOP2 study. Breast 2021. [DOI: 10.1016/s0960-9776(21)00222-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
5
|
Kolberg HC, Kühn T, Krajewska M, Bauerfeind I, Fehm TN, Fleige B, Helms G, Lebeau A, Stäbler A, Schmatloch S, Hauschild M, Schwentner L, Schrenk P, Loibl S, Untch M, Kolberg-Liedtke C. Correction: Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases - a transSENTINA Analysis. Geburtshilfe Frauenheilkd 2020; 80:e290. [PMID: 33335331 PMCID: PMC7738234 DOI: 10.1055/a-1336-7155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
| | - Thorsten Kühn
- Interdisciplinary Breast Centre, Department of Gynecology and Obstetrics, Klinikum Esslingen, Esslingen, Germany
| | - Maja Krajewska
- Institute of Biometry and Clinical Epidemiology, Charité - University Hospital Berlin, Berlin, Germany
| | - Ingo Bauerfeind
- Department of Gynecology and Obstetrics, Klinikum Landshut, Landshut, Germany
| | - Tanja N Fehm
- Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
| | - Barbara Fleige
- Department of Pathology, Multidisciplinary Breast Centre, Helios Klinikum Berlin-Buch, Berlin, Germany
| | - Gisela Helms
- Department of Gynecology and Obstetrics, University Medical Centre Tübingen, Tübingen, Germany
| | - Annette Lebeau
- Department of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Annette Stäbler
- Department of Pathology, University of Tübingen, Tübingen, Germany
| | | | - Maik Hauschild
- Department of Gynecology and Obstetrics, Health Center Fricktal, Rheinfelden, Switzerland
| | | | - Peter Schrenk
- Breast Competence Centre, Kepler University Hospital, Linz, Austria
| | | | - Michael Untch
- Department of Gynecology and Obstetrics, Multidisciplinary Breast Centre, Helios Klinikum Berlin-Buch, Berlin, Germany
| | | |
Collapse
|
6
|
Kolberg HC, Kühn T, Krajewska M, Bauerfeind I, Fehm TN, Fleige B, Helms G, Lebeau A, Stäbler A, Schmatloch S, Hausschild M, Schwentner L, Schrenk P, Loibl S, Untch M, Kolberg-Liedtke C. Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases - a transSENTINA Analysis. Geburtshilfe Frauenheilkd 2020; 80:1229-1236. [PMID: 33293731 PMCID: PMC7714621 DOI: 10.1055/a-1298-3453] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Accepted: 10/30/2020] [Indexed: 12/20/2022] Open
Abstract
Background
Among patients with breast cancer undergoing neoadjuvant chemotherapy (NACT), the association between pathological complete remission (pCR) in the breast and clinical/pathological parameters is well established, whereas the association between these parameters and residual axillary involvement after NACT remains unclear.
Methods
Patients with clinically occult nodal metastases (i.e. negative by clinical assessment but positive by SLNB prior to NACT, i.e. Arm B of the SENTINA trial) were included in the presented analysis. All patients received a second sentinel lymph node biopsy (SLNB) and axillary dissection after NACT. Univariate and multivariate analyses were carried out to evaluate the association between clinical/pathological parameters and axillary involvement after NACT.
Results
Arm B of the SENTINA study contained 360 patients, 318 of which were evaluable for this analysis. After NACT, 71/318 (22.3%) patients had involved SLNs or non-SLNs after NACT. Overall, 71/318 (22.3%) patients achieved a pCR in the breast. Associations of extranodal spread, lack of multifocality and pCR in the breast with residual axillary burden were statistically significant. In a descriptive analysis including all patients with clinically negative axilla before NACT in the SENTINA trial 1.2% of triple negative (TN) patients and 0.5% of HER/2 positive patients had residual axillary disease in case of a breast pCR.
Conclusions
Patients in the SENTINA trial with clinically negative axilla and involved SLNs still carried a significant risk of nodal metastases after NACT. However, the risk of residual axillary burden was particularly low in TN and HER/2 positive tumors in case of a breast pCR.
Collapse
Affiliation(s)
| | - Thorsten Kühn
- Interdisciplinary Breast Centre, Department of Gynecology and Obstetrics, Klinikum Esslingen, Esslingen, Germany
| | - Maja Krajewska
- Institute of Biometry and Clinical Epidemiology, Charité - University Hospital Berlin, Berlin, Germany
| | - Ingo Bauerfeind
- Department of Gynecology and Obstetrics, Klinikum Landshut, Landshut, Germany
| | - Tanja N Fehm
- Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
| | - Barbara Fleige
- Department of Pathology, Multidisciplinary Breast Centre, Helios Klinikum Berlin-Buch, Berlin, Germany
| | - Gisela Helms
- Department of Gynecology and Obstetrics, University Medical Centre Tübingen, Tübingen, Germany
| | - Annette Lebeau
- Department of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Annette Stäbler
- Department of Pathology, University of Tübingen, Tübingen, Germany
| | | | - Maik Hausschild
- Department of Gynecology and Obstetrics, Health Center Fricktal, Rheinfelden, Switzerland
| | | | - Peter Schrenk
- Breast Competence Centre, Kepler University Hospital, Linz, Austria
| | | | - Michael Untch
- Department of Gynecology and Obstetrics, Multidisciplinary Breast Centre, Helios Klinikum Berlin-Buch, Berlin, Germany
| | | |
Collapse
|
7
|
Bjelic-Radisic V, Fitzal F, Knauer M, Steger G, Egle D, Greil R, Schrenk P, Balic M, Singer C, Exner R, Soelkner L, Gnant M. Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial. BMC Cancer 2020; 20:392. [PMID: 32375735 PMCID: PMC7204290 DOI: 10.1186/s12885-020-06894-2] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2019] [Accepted: 04/23/2020] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND The ABCSG-28 trial compared primary surgery followed by systemic therapy versus primary systemic therapy without surgery in patients with de novo stage IV BC. The present report describes QoL results of this trial. METHODS Ninety patients with primary operable MBC were randomised to surgery of the primary tumor followed by systemic therapy or to primary systemic therapy without surgery. QoL analyses covering the results at baseline, 6,12,18 and 24 months follow up of 79 (88%) patients, was assessed with the EORTC QLQ-C30 and QLQ-BR23 questionnaires. RESULTS There were no statistically significant differences in any of the scales of the QLQ-C30 and QLQ-BR23 questionnaires between the two groups over the time. Baseline global health status and physical functioning were predictors for OS (patients with a higher score lived longer (p=0.0250, p=0.0225; p=0.0355, p=0.0355)). Global health status, social functioning scale, breast symptoms and future perspective were predictors for longer TTPd (p=0.0244; p=0.0140, p=0.020; p=0.0438, p=0.0123). Patients in both arms reported significant improvement on the emotional functioning scale. Cognitive functioning decreased over time in both groups. Younger women had clinically relevant better physical and sexual functioning scores (p=0.039 and 0.024). CONCLUSION Primary surgery does not improve nor alter QoL of patients with de novo stage IV BC. Global health status and physical functioning were predictors for OS and could be use as additional marker for prediction of OS and TTTd in patients with de novo stage IV BC. TRIAL REGISTRATION The trial is registered on clinicaltrial.gov (NCT01015625, date of registration:18/11/2009).
Collapse
Affiliation(s)
- V Bjelic-Radisic
- Breast Unit, University Hospital Wuppertal, Heusnerstraße 40, 42283, Wuppertal, Germany. .,Department of Gynecology and Obstetrics, Medical University Graz, Graz, Austria.
| | - F Fitzal
- Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - M Knauer
- Breast Unit, Kantonsspital St. Gallen, St. Gallen, Switzerland
| | - G Steger
- Department of Internal Medicine, Medical University of Vienna, Vienna, Austria
| | - D Egle
- Department of Gynecology and Obstetrics, Medical University Innsbruck, Inssbruck, Austria
| | - R Greil
- Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Laboratory for Immunological and Molecular cancer Reseasrch, Paracelsus Medical University Salzburg, Salzburg, Austria
| | - P Schrenk
- Department of Surgery, Medical University Linz, Linz, Austria
| | - M Balic
- Division of Oncology, Department of Internal Medicine and Comprehensive Cancer Center, Medical University Graz, Graz, Austria
| | - Ch Singer
- Department of Gynecology and Obstetrics, Medical University Vienna, Vienna, Austria
| | - R Exner
- Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - L Soelkner
- Statistics Department, Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna, Austria
| | - Michael Gnant
- Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | | |
Collapse
|
8
|
Kolberg HC, Liedtke C, Bauerfeind I, Fehm T, Fleige B, Hauschild M, Helms G, Lebeau A, Schmatloch S, Schrenk P, Schwentner L, Stäbler A, Loibl S, Untch M, Kühn T. Abstract PD8-02: Residual axillary involvement in early breast cancer in patients with positive sentinel nodes after neoadjuvant chemotherapy (NACT). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd8-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:The association between pathological complete remission (pCR) in the breast and clinical/pathological parameters is well established, whereas the role of these parameters in the prediction of residual axillary involvement after NACT is unclear. The goal is to identify a subset of patients who do not need axillary treatment. We used data from Arm B of the SENTINA trial to analyze this association.
Methods:Patients from arm B of the SENTINA trial with clinically and sonographically unsuspicious axillary nodes but with histologically proven involvement of SLNs prior to NACT were analyzed. All patients had SLNB and axillary dissection after NACT. Univariate analyses were performed to evaluate the association between clinical/pathological parameters and axillary involvement after NACT.
Results:Arm B of the SENTINA study contained 360 patients, 318 of which were evaluable with respect to the above parameters. After NACT 71/318 (22.3%) patients had involved SLNs or non-SLNs; 71/318 (22.3%) had a pCR in the breast. We observed a significant association between pCR in the breast and negative ER status, negative PR status, positive HER2 status, triple negative (TN) status, tumor size before and after NACT, multifocality, lobular morphology and axillary involvement after NACT. Regarding residual axillary burden only the associations with lobular morphology, extracapsular invasion, multifocality, positive HER2 status and pCR in the breast were statistically significant.
Conclusion:Our analysis demonstrates that patients enrolled in the SENTINA trial with clinically and sonographically unsuspicious axillary nodes but proven histological involvement of SLNs prior to NACT have positive axillary nodes in 22.3 % after NACT. This rate is confirming similar results from other groups. Although we found statistically significant associations between pCR in the breast and clinical/pathological parameters, only the association between lobular type, extracapsular invasion, positive HER2 status and pCR in the breast and residual axillary involvement after NACT were statistically significant. We cannot clearly identify a subset of patients for whom axillary treatment after NACT could be safely omitted if SLNs were positive. Our data are well in line with recently presented data demonstrating that the association between pCR in the breast and free axillary nodes after NACT is particularly strong in patients with TN and HER2 positive tumors. This question will be addressed in future trials currently under development.
Citation Format: Kolberg H-C, Liedtke C, Bauerfeind I, Fehm T, Fleige B, Hauschild M, Helms G, Lebeau A, Schmatloch S, Schrenk P, Schwentner L, Stäbler A, Loibl S, Untch M, Kühn T. Residual axillary involvement in early breast cancer in patients with positive sentinel nodes after neoadjuvant chemotherapy (NACT) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD8-02.
Collapse
Affiliation(s)
- H-C Kolberg
- Marienhospital Bottrop, Bottrop, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Klinikum Landshut, Landshut, Germany; Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Spital Rheinfelden, Rheinfelden, Switzerland; Universitätsklinikum Tübingen, Tübingen, Germany; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Elisabeth-Krankenhaus Kassel, Kassel, Germany; Kepler Universitätsklinikum, Linz, Austria; Gynova, Reith, Austria; German Breast Group, Neu-Isenburg, Germany; Klinikum Esslingen, Esslingen, Germany
| | - C Liedtke
- Marienhospital Bottrop, Bottrop, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Klinikum Landshut, Landshut, Germany; Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Spital Rheinfelden, Rheinfelden, Switzerland; Universitätsklinikum Tübingen, Tübingen, Germany; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Elisabeth-Krankenhaus Kassel, Kassel, Germany; Kepler Universitätsklinikum, Linz, Austria; Gynova, Reith, Austria; German Breast Group, Neu-Isenburg, Germany; Klinikum Esslingen, Esslingen, Germany
| | - I Bauerfeind
- Marienhospital Bottrop, Bottrop, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Klinikum Landshut, Landshut, Germany; Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Spital Rheinfelden, Rheinfelden, Switzerland; Universitätsklinikum Tübingen, Tübingen, Germany; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Elisabeth-Krankenhaus Kassel, Kassel, Germany; Kepler Universitätsklinikum, Linz, Austria; Gynova, Reith, Austria; German Breast Group, Neu-Isenburg, Germany; Klinikum Esslingen, Esslingen, Germany
| | - T Fehm
- Marienhospital Bottrop, Bottrop, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Klinikum Landshut, Landshut, Germany; Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Spital Rheinfelden, Rheinfelden, Switzerland; Universitätsklinikum Tübingen, Tübingen, Germany; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Elisabeth-Krankenhaus Kassel, Kassel, Germany; Kepler Universitätsklinikum, Linz, Austria; Gynova, Reith, Austria; German Breast Group, Neu-Isenburg, Germany; Klinikum Esslingen, Esslingen, Germany
| | - B Fleige
- Marienhospital Bottrop, Bottrop, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Klinikum Landshut, Landshut, Germany; Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Spital Rheinfelden, Rheinfelden, Switzerland; Universitätsklinikum Tübingen, Tübingen, Germany; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Elisabeth-Krankenhaus Kassel, Kassel, Germany; Kepler Universitätsklinikum, Linz, Austria; Gynova, Reith, Austria; German Breast Group, Neu-Isenburg, Germany; Klinikum Esslingen, Esslingen, Germany
| | - M Hauschild
- Marienhospital Bottrop, Bottrop, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Klinikum Landshut, Landshut, Germany; Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Spital Rheinfelden, Rheinfelden, Switzerland; Universitätsklinikum Tübingen, Tübingen, Germany; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Elisabeth-Krankenhaus Kassel, Kassel, Germany; Kepler Universitätsklinikum, Linz, Austria; Gynova, Reith, Austria; German Breast Group, Neu-Isenburg, Germany; Klinikum Esslingen, Esslingen, Germany
| | - G Helms
- Marienhospital Bottrop, Bottrop, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Klinikum Landshut, Landshut, Germany; Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Spital Rheinfelden, Rheinfelden, Switzerland; Universitätsklinikum Tübingen, Tübingen, Germany; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Elisabeth-Krankenhaus Kassel, Kassel, Germany; Kepler Universitätsklinikum, Linz, Austria; Gynova, Reith, Austria; German Breast Group, Neu-Isenburg, Germany; Klinikum Esslingen, Esslingen, Germany
| | - A Lebeau
- Marienhospital Bottrop, Bottrop, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Klinikum Landshut, Landshut, Germany; Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Spital Rheinfelden, Rheinfelden, Switzerland; Universitätsklinikum Tübingen, Tübingen, Germany; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Elisabeth-Krankenhaus Kassel, Kassel, Germany; Kepler Universitätsklinikum, Linz, Austria; Gynova, Reith, Austria; German Breast Group, Neu-Isenburg, Germany; Klinikum Esslingen, Esslingen, Germany
| | - S Schmatloch
- Marienhospital Bottrop, Bottrop, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Klinikum Landshut, Landshut, Germany; Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Spital Rheinfelden, Rheinfelden, Switzerland; Universitätsklinikum Tübingen, Tübingen, Germany; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Elisabeth-Krankenhaus Kassel, Kassel, Germany; Kepler Universitätsklinikum, Linz, Austria; Gynova, Reith, Austria; German Breast Group, Neu-Isenburg, Germany; Klinikum Esslingen, Esslingen, Germany
| | - P Schrenk
- Marienhospital Bottrop, Bottrop, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Klinikum Landshut, Landshut, Germany; Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Spital Rheinfelden, Rheinfelden, Switzerland; Universitätsklinikum Tübingen, Tübingen, Germany; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Elisabeth-Krankenhaus Kassel, Kassel, Germany; Kepler Universitätsklinikum, Linz, Austria; Gynova, Reith, Austria; German Breast Group, Neu-Isenburg, Germany; Klinikum Esslingen, Esslingen, Germany
| | - L Schwentner
- Marienhospital Bottrop, Bottrop, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Klinikum Landshut, Landshut, Germany; Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Spital Rheinfelden, Rheinfelden, Switzerland; Universitätsklinikum Tübingen, Tübingen, Germany; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Elisabeth-Krankenhaus Kassel, Kassel, Germany; Kepler Universitätsklinikum, Linz, Austria; Gynova, Reith, Austria; German Breast Group, Neu-Isenburg, Germany; Klinikum Esslingen, Esslingen, Germany
| | - A Stäbler
- Marienhospital Bottrop, Bottrop, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Klinikum Landshut, Landshut, Germany; Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Spital Rheinfelden, Rheinfelden, Switzerland; Universitätsklinikum Tübingen, Tübingen, Germany; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Elisabeth-Krankenhaus Kassel, Kassel, Germany; Kepler Universitätsklinikum, Linz, Austria; Gynova, Reith, Austria; German Breast Group, Neu-Isenburg, Germany; Klinikum Esslingen, Esslingen, Germany
| | - S Loibl
- Marienhospital Bottrop, Bottrop, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Klinikum Landshut, Landshut, Germany; Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Spital Rheinfelden, Rheinfelden, Switzerland; Universitätsklinikum Tübingen, Tübingen, Germany; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Elisabeth-Krankenhaus Kassel, Kassel, Germany; Kepler Universitätsklinikum, Linz, Austria; Gynova, Reith, Austria; German Breast Group, Neu-Isenburg, Germany; Klinikum Esslingen, Esslingen, Germany
| | - M Untch
- Marienhospital Bottrop, Bottrop, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Klinikum Landshut, Landshut, Germany; Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Spital Rheinfelden, Rheinfelden, Switzerland; Universitätsklinikum Tübingen, Tübingen, Germany; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Elisabeth-Krankenhaus Kassel, Kassel, Germany; Kepler Universitätsklinikum, Linz, Austria; Gynova, Reith, Austria; German Breast Group, Neu-Isenburg, Germany; Klinikum Esslingen, Esslingen, Germany
| | - T Kühn
- Marienhospital Bottrop, Bottrop, Germany; Charité - Universitätsmedizin Berlin, Berlin, Germany; Klinikum Landshut, Landshut, Germany; Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Helios-Klinikum Berlin-Buch, Berlin, Germany; Spital Rheinfelden, Rheinfelden, Switzerland; Universitätsklinikum Tübingen, Tübingen, Germany; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Elisabeth-Krankenhaus Kassel, Kassel, Germany; Kepler Universitätsklinikum, Linz, Austria; Gynova, Reith, Austria; German Breast Group, Neu-Isenburg, Germany; Klinikum Esslingen, Esslingen, Germany
| |
Collapse
|
9
|
Strobl SA, Dubsky P, Exner R, Gnant M, Jakesz R, Tausch C, Wette V, Heck D, Luisser I, Bjelic-Radisic V, Schrenk P, Poyssl C, Mathis J, Fitzal F. Abstract P3-03-24: ABCSG 33 - A multi center registry to evaluate the affect of macro metastasis in sentinel lymph node on survival. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-03-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Sentinel lymph node dissection identifies nodal positivity in early breast cancer. Trials like the ACOSOG Z0011 trial tried to show that the waiver of axillary dissection in nodal positive breast cancer (BC) has no effect on the oncologic outome, however real world data are rare and the role of adjuvant regional radiotherapy is still disputed in this respect.
Objective:
We initiated a multicenter observational registry to investigate omission of axillary lymph node dissection in nodal positive early BC.
Design and Setting:
The 18 sites participating in Austria and Switzerland included from 2014 to 2017 178 patients in this trail.
Patients:
Women with unilateral invasive lymph node positive BC with one or two sentinel lymph node makrometastases, who did not undergo axillary lymph node dissection were included.
Results:
We had a median follow up time of 3.1 years (range between 0.5 and 10.5 years), the median patient age is 63.6 years (range between 33 – 93 years). In 16.9% women had a G1 Grading, 53.1% had G2 tumor and 29.9% had a G3 tumor. Multifocality was seen in 18.1% of the patients. Luminal A tumors were seen in 16 (8.9%) and Luminal B in 82 (46.1%). Fourteen (7.8%) patients in this cohort had HER2 positive BC. In one (0.5%) local recurrence of the axilla occurred. Three (1.7%) of 178 patients died due to BC recurrence.
Conclusion:
Patients with macro metastasis in the sentinel lymph node, treated with breast conserving surgery and whole breast radiation did not have an increased risk of BC recurrence.
Therefore the authors assume that axillary dissection in patients with early stage BC and macro metastasis is not necessary in this patient cohort.
Citation Format: Strobl SA, Dubsky P, Exner R, Gnant M, Jakesz R, Tausch C, Wette V, Heck D, Luisser I, Bjelic-Radisic V, Schrenk P, Poyssl C, Mathis J, Fitzal F. ABCSG 33 - A multi center registry to evaluate the affect of macro metastasis in sentinel lymph node on survival [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-03-24.
Collapse
Affiliation(s)
- SA Strobl
- Medical University of Vienna, Vienna, Austria; Brust Zentrum Zürich, Zürich, Switzerland; Medical University of Graz, Graz, Austria; General Hospital Linz, Linz, Austria; Brustzentrum Wette, St. Veit an der Glan, Austria; State Hospital Guessing, Guessing, Austria; Barmherzige Schwestern Linz, Linz, Austria; State Hospital Feldkirch, Feldkirch, Austria; State Hospital Dornbirn, Dornbirn, Austria
| | - P Dubsky
- Medical University of Vienna, Vienna, Austria; Brust Zentrum Zürich, Zürich, Switzerland; Medical University of Graz, Graz, Austria; General Hospital Linz, Linz, Austria; Brustzentrum Wette, St. Veit an der Glan, Austria; State Hospital Guessing, Guessing, Austria; Barmherzige Schwestern Linz, Linz, Austria; State Hospital Feldkirch, Feldkirch, Austria; State Hospital Dornbirn, Dornbirn, Austria
| | - R Exner
- Medical University of Vienna, Vienna, Austria; Brust Zentrum Zürich, Zürich, Switzerland; Medical University of Graz, Graz, Austria; General Hospital Linz, Linz, Austria; Brustzentrum Wette, St. Veit an der Glan, Austria; State Hospital Guessing, Guessing, Austria; Barmherzige Schwestern Linz, Linz, Austria; State Hospital Feldkirch, Feldkirch, Austria; State Hospital Dornbirn, Dornbirn, Austria
| | - M Gnant
- Medical University of Vienna, Vienna, Austria; Brust Zentrum Zürich, Zürich, Switzerland; Medical University of Graz, Graz, Austria; General Hospital Linz, Linz, Austria; Brustzentrum Wette, St. Veit an der Glan, Austria; State Hospital Guessing, Guessing, Austria; Barmherzige Schwestern Linz, Linz, Austria; State Hospital Feldkirch, Feldkirch, Austria; State Hospital Dornbirn, Dornbirn, Austria
| | - R Jakesz
- Medical University of Vienna, Vienna, Austria; Brust Zentrum Zürich, Zürich, Switzerland; Medical University of Graz, Graz, Austria; General Hospital Linz, Linz, Austria; Brustzentrum Wette, St. Veit an der Glan, Austria; State Hospital Guessing, Guessing, Austria; Barmherzige Schwestern Linz, Linz, Austria; State Hospital Feldkirch, Feldkirch, Austria; State Hospital Dornbirn, Dornbirn, Austria
| | - C Tausch
- Medical University of Vienna, Vienna, Austria; Brust Zentrum Zürich, Zürich, Switzerland; Medical University of Graz, Graz, Austria; General Hospital Linz, Linz, Austria; Brustzentrum Wette, St. Veit an der Glan, Austria; State Hospital Guessing, Guessing, Austria; Barmherzige Schwestern Linz, Linz, Austria; State Hospital Feldkirch, Feldkirch, Austria; State Hospital Dornbirn, Dornbirn, Austria
| | - V Wette
- Medical University of Vienna, Vienna, Austria; Brust Zentrum Zürich, Zürich, Switzerland; Medical University of Graz, Graz, Austria; General Hospital Linz, Linz, Austria; Brustzentrum Wette, St. Veit an der Glan, Austria; State Hospital Guessing, Guessing, Austria; Barmherzige Schwestern Linz, Linz, Austria; State Hospital Feldkirch, Feldkirch, Austria; State Hospital Dornbirn, Dornbirn, Austria
| | - D Heck
- Medical University of Vienna, Vienna, Austria; Brust Zentrum Zürich, Zürich, Switzerland; Medical University of Graz, Graz, Austria; General Hospital Linz, Linz, Austria; Brustzentrum Wette, St. Veit an der Glan, Austria; State Hospital Guessing, Guessing, Austria; Barmherzige Schwestern Linz, Linz, Austria; State Hospital Feldkirch, Feldkirch, Austria; State Hospital Dornbirn, Dornbirn, Austria
| | - I Luisser
- Medical University of Vienna, Vienna, Austria; Brust Zentrum Zürich, Zürich, Switzerland; Medical University of Graz, Graz, Austria; General Hospital Linz, Linz, Austria; Brustzentrum Wette, St. Veit an der Glan, Austria; State Hospital Guessing, Guessing, Austria; Barmherzige Schwestern Linz, Linz, Austria; State Hospital Feldkirch, Feldkirch, Austria; State Hospital Dornbirn, Dornbirn, Austria
| | - V Bjelic-Radisic
- Medical University of Vienna, Vienna, Austria; Brust Zentrum Zürich, Zürich, Switzerland; Medical University of Graz, Graz, Austria; General Hospital Linz, Linz, Austria; Brustzentrum Wette, St. Veit an der Glan, Austria; State Hospital Guessing, Guessing, Austria; Barmherzige Schwestern Linz, Linz, Austria; State Hospital Feldkirch, Feldkirch, Austria; State Hospital Dornbirn, Dornbirn, Austria
| | - P Schrenk
- Medical University of Vienna, Vienna, Austria; Brust Zentrum Zürich, Zürich, Switzerland; Medical University of Graz, Graz, Austria; General Hospital Linz, Linz, Austria; Brustzentrum Wette, St. Veit an der Glan, Austria; State Hospital Guessing, Guessing, Austria; Barmherzige Schwestern Linz, Linz, Austria; State Hospital Feldkirch, Feldkirch, Austria; State Hospital Dornbirn, Dornbirn, Austria
| | - C Poyssl
- Medical University of Vienna, Vienna, Austria; Brust Zentrum Zürich, Zürich, Switzerland; Medical University of Graz, Graz, Austria; General Hospital Linz, Linz, Austria; Brustzentrum Wette, St. Veit an der Glan, Austria; State Hospital Guessing, Guessing, Austria; Barmherzige Schwestern Linz, Linz, Austria; State Hospital Feldkirch, Feldkirch, Austria; State Hospital Dornbirn, Dornbirn, Austria
| | - J Mathis
- Medical University of Vienna, Vienna, Austria; Brust Zentrum Zürich, Zürich, Switzerland; Medical University of Graz, Graz, Austria; General Hospital Linz, Linz, Austria; Brustzentrum Wette, St. Veit an der Glan, Austria; State Hospital Guessing, Guessing, Austria; Barmherzige Schwestern Linz, Linz, Austria; State Hospital Feldkirch, Feldkirch, Austria; State Hospital Dornbirn, Dornbirn, Austria
| | - F Fitzal
- Medical University of Vienna, Vienna, Austria; Brust Zentrum Zürich, Zürich, Switzerland; Medical University of Graz, Graz, Austria; General Hospital Linz, Linz, Austria; Brustzentrum Wette, St. Veit an der Glan, Austria; State Hospital Guessing, Guessing, Austria; Barmherzige Schwestern Linz, Linz, Austria; State Hospital Feldkirch, Feldkirch, Austria; State Hospital Dornbirn, Dornbirn, Austria
| |
Collapse
|
10
|
Kolberg HC, Liedtke C, Bauerfeind I, Fehm TN, Fleige B, Hauschild M, Helms G, Lebeau A, Schmatloch S, Schrenk P, Schwentner L, Staebler A, Von Minckwitz G, Loibl S, Untch M, Kühn T. Association of clinical/pathological parameters with axillary involvement in early breast cancer in patients with limited sentinel node involvement (< 3 LK) after neoadjuvant chemotherapy (NACT). J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Ingo Bauerfeind
- Department of Obstetrics and Gynecology and Interdisciplinary Breast Cancer Center, Klinikum Landshut, Landshut, Germany
| | | | | | | | - Gisela Helms
- Universitatsklinikum Tubingen, Tubingen, Germany
| | - Annette Lebeau
- Institut für Pathologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr, Hamburg, Germany
| | | | | | | | | | | | | | - Michael Untch
- Department of Gynecology and Obstetrics, Helios Klinikum Berlin-Buch, Berlin, Germany
| | | |
Collapse
|
11
|
Gschwantler-Kaulich D, Schrenk P, Bjelic-Radisic V, Unterrieder K, Leser C, Fink-Retter A, Salama M, Singer C. Corrigendum to "Mesh versus acellular dermal matrix in immediate implant-based breast reconstruction - A prospective randomized trial" [Eur J Surg Oncol 42 (5) (2016) 665-671]. Eur J Surg Oncol 2017; 43:1380-1381. [PMID: 28526188 DOI: 10.1016/j.ejso.2017.05.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Affiliation(s)
- D Gschwantler-Kaulich
- Medical University of Vienna, Breast Cancer Center, Department of Gynaecological Oncology, Waehringer Guertel 18-20, 1090 Vienna, Austria.
| | - P Schrenk
- AKH Linz Breast Cancer Center, Krankenhausstrasse 9, 4021 Linz, Austria
| | - V Bjelic-Radisic
- Medical University of Graz, Department of Gynaecology, Auenbruggerplatz 1, 8036 Graz, Austria
| | - K Unterrieder
- Private Hospital Villach, Breast Cancer Center, Department of Gynaecology, Dr.-Walter-Hochsteiner-Straße 4, 9504 Villach, Austria
| | - C Leser
- Medical University of Vienna, Breast Cancer Center, Department of Gynaecological Oncology, Waehringer Guertel 18-20, 1090 Vienna, Austria
| | - A Fink-Retter
- Medical University of Vienna, Breast Cancer Center, Department of Gynaecological Oncology, Waehringer Guertel 18-20, 1090 Vienna, Austria
| | - M Salama
- Otto Wagner Hospital, Department of Surgery, Baumgartner Hoehe 1, 1140 Vienna, Austria
| | - C Singer
- Medical University of Vienna, Breast Cancer Center, Department of Gynaecological Oncology, Waehringer Guertel 18-20, 1090 Vienna, Austria
| |
Collapse
|
12
|
Fitzal F, Balic M, Bjelic-Radisic V, Hubalek M, Singer CF, Steger GG, Marth C, Schrenk P, Knauer M, Haid A, Wette V, Luisser I, Greil R, Fuegger R, Swoboda U, Soelkner L, Gnant M. Primary operation in synchroneous metastasized invasive breast cancer patients: First oncologic outcomes of the prospective randomized phase III ABCSG 28 POSYTIVE trial. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.557] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
557 Background: The ABCSG 28 Posytive trial compared primary surgery versus primary systemic therapy without surgery in stage IV breast cancer patients. The primary aim was to investigate whether immediate resection of the primary tumor followed by standard systemic therapy improves median survival compared with no surgical resection (NCT01015625). The trial had to be stopped early due insufficient recruitment. Methods: Untreated stage IV breast cancer patients with the primary in situ were randomly assigned to either surgery of the primary versus no surgery followed by systemic therapy between 2011 and 2015 in 15 breast health centers in Austria. Systemic therapy included endocrine therapy or chemotherapy. Patients were routinely followed every 3-6 months. Primary endpoint was median survival. Results: 90 patients (45 with surgery, 45 with primary systemic therapy without surgery) were randomized. Stratification criteria were age, endocrine responsiveness, her2 expression, planned first line therapy and bone only versus other metastases. Patients in the surgery arm had more cT3 breast cancer (22% versus 7%) and more cN2 staging (16% versus 4%) as well as more her2 positive breast cancer cases (27% versus 18%). The median follow up was 37.5 months and immunohistochemical subtype analysis showed 9% basal like, 22% her2 positive, 51% luminal A and 13% luminal B cancers. Both groups were well balanced regarding first line treatment (endocrine versus chemotherapy) however, there were more taxane treated patients in the no surgery group (24.4 versus 15.6%). The median survival in the surgery arm was 34.6 months versus 54.8 months in the no surgery arm without statistical significance (HR 0.691 CI 0.358 – 1.333; p=0.267). Time to distant progression was insignificantly longer in the no surgery arm (surgery arm 13.9 versus no surgery arm 29.0 months). Conclusions: This first analysis of the prospective randomized phase III trial POSYTIVE-ABCSG-28 demonstrated no benefit in overall survival for immediate surgery of the primary in de novo stage IV breast cancer patients. Clinical trial information: NCT01015625.
Collapse
Affiliation(s)
| | | | - Vesna Bjelic-Radisic
- Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria
| | | | - Christian F. Singer
- Medical University of Vienna, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Vienna, Austria
| | | | - Christian Marth
- AGO-A and Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
| | | | - Michael Knauer
- Academic Teaching Hospital Feldkirch, Feldkirch, Austria
| | - Anton Haid
- Breast Cancer Center Vorarlberg, Feldkirch, Austria
| | - Viktor Wette
- Breast Center, Doctor's Office Wette, St.Veit an Der Glan, Austria
| | | | - Richard Greil
- Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria
| | | | | | | | - Michael Gnant
- Department of Surgery and Comprehensive Cancer Center and Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna, Austria
| |
Collapse
|
13
|
Liedtke C, Kolberg HC, Kerschke L, Goerlich D, Bauerfeind I, Fehm TN, Fleige B, Hauschild M, Helms G, Lebeau A, Schmatloch S, Schrenk P, Schwentner L, Staebler A, Von Minckwitz G, Loibl S, Untch M, Kuehn T. Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients converting from cN+ to ycN0 through primary systemic therapy (PST). J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
560 Background: Optimization of axillary staging in patients converting from cN+ to ycN0 through PST is needed. The aim of this analysis was to develop a nomogram predicting the probability of ypN+ after PST based on clinical/pathological parameters. Methods: Patients converting from cN+ to ycN0 through PST from a prospective study (SENTINA arm C) were included. Univariate/multivariate analyses were carried out for 14 clinical/pathological parameters to predict ypN+ using logistic regression models. Odds ratios and 95% confidence intervals were reported. Model performance was assessed by leave-one-out cross-validation (LOOCV at .5 cut-offs) and ROC analyses. Calculations were performed using the SAS Software (Version 9.4). Results: 553 patients were assessed. Stepwise backward variable selection based on a multivariate analysis of all significant parameters resulted in a model (5M, Table, N = 369 evaluable) including ER (3.81; 2.25-6.44), multifocality (2.22; 1.26-3.92), LVI (9.16; 4.68-17.90), detection of SLN after PST (.50; .26-.95) and ycT (1.03; 1.01-1.06). In LOOCV, this model had an area under the curve of .81. Multivariate analysis of parameters available preoperatively showed an association between ypN0/ypN+, ER and ycT. Full subset selection resulted in a model (2M, N = 414) containing only ER (4.36; 2.80, 6.81) and ycT (1.04; 1.02, 1.07). Conclusions: A prediction model including parameters evaluable before/after definitive surgery resulted in a nomogram with acceptable accuracy. Limitation to parameters evaluable before surgery (i.e. ER, ycT) showed reduced accuracy that was comparable/superior to accuracy of using individual parameters. Since tumor biology was the strongest parameter in our models, we hypothesize that modern tumor biologic parameters such as gene expression profiling might optimize prediction of axillary status after PST improving patient counseling. [Table: see text]
Collapse
Affiliation(s)
- Cornelia Liedtke
- University of Schleswig-Holstein Campus Luebeck, Lübeck, Germany
| | | | | | | | - Ingo Bauerfeind
- Department of Obstetrics and Gynecology and Interdisciplinary Breast Cancer Center, Klinikum Landshut, Landshut, Germany
| | | | | | | | - Gisela Helms
- Universitatsklinikum Tubingen, Tubingen, Germany
| | - Annette Lebeau
- Institut für Pathologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr, Hamburg, Germany
| | | | | | - Lukas Schwentner
- Department of Gynecology and Obstetrics University Ulm, Ulm, Germany
| | | | | | | | | | | |
Collapse
|
14
|
Bjelic-Radisic V, Fitzal F, Steger GG, Marth C, Balic M, Knauer M, Singer CF, Hubalek M, Schrenk P, Haid A, Wette V, Swoboda U, Fuegger R, Greil R, Soelkner L, Gnant M. Primary surgery versus no surgery in synchronous metastastic breast cancer: Patient-reported outcomes of the ABCSG 28 Posytive trial. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.1074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1074 Background: The ABCSG 28 Posytive trial compared primary surgery versus primary systemic therapy without surgery in synchronous metastatic breast cancer. The primary aim of the study was to investigate whether immediate resection of the primary tumor followed by standard systemic therapy improves median survival compared with no surgical resection (NCT01015625). This report describes quality-of-life (QoL) results. Methods: Patients were randomized between 2011 and 2015. Patients completed the EORTC QLQ-C30 and EORTC QLQ-BR 23 before treatment and every 6 months during follow-up. Results: 90 patients (45 with surgery, 45 with primary systemic therapy without surgery) from 15 centers were included in the QoL analysis. At 6 months patients after surgery reported more insomnia, breast symptoms and arm symptoms than patients without surgery, but these differences were no longer present at later follow-up visits. In the univariate and multivariate analysis the global health status and physical functioning scales of EORTC QLQ C30 were statistically significant predictors for OS and TTP (p < 0.05). Over a 24-month follow-up, patients > 60 years showed more QoL impairments than those < 60 years, independent of treatment. Patients < 60 years had better physical functioning and less fatigue, appetite loss, constipation and breast symptoms than older patients. There were no differences in QoL between patients with bone metastases vs those with visceral ± bone metastases. Conclusions: In patients with primary metastatic breast cancer primary surgery does not appear to improve QoL. Global health status and physical functioning scales of EORTC QLQ-C30 appears to be a predictive factor for OS and TTP. Clinical trial information: NCT01015625.
Collapse
Affiliation(s)
- Vesna Bjelic-Radisic
- Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria
| | | | | | - Christian Marth
- AGO-A and Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
| | | | - Michael Knauer
- Academic Teaching Hospital Feldkirch, Feldkirch, Austria
| | - Christian F. Singer
- Medical University of Vienna, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Vienna, Austria
| | | | | | - Anton Haid
- Breast Cancer Center Vorarlberg, Feldkirch, Austria
| | - Viktor Wette
- Breast Center, Doctor's Office Wette, St.Veit an Der Glan, Austria
| | | | | | - Richard Greil
- Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria
| | | | - Michael Gnant
- Department of Surgery and Comprehensive Cancer Center and Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna, Austria
| | | |
Collapse
|
15
|
Liedtke C, Kolberg HC, Kerschke L, Goerlich D, Bauerfeind I, Fehm T, Fleige B, Hauschild M, Helms G, Lebeau A, Schmatloch S, Schrenk P, Schwentner L, Staebler A, von Minckwitz G, Loibl S, Untch M, Kuehn T. Abstract P3-13-06: Development and validation of a nomogram predicting pathological axillary status (ypN0 vs. ypN+) in a subgroup of patients converting from cN+ to ycN0 through neoadjuvant therapy (NAT) – A transSENTINA substudy. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-13-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Particularly among patients converting from cN+ to ycN0 status through neoadjuvant therapy (NAT) the optimal method and extent of axillary staging is unclear. The aim of this analysis was to develop a nomogram predicting the probability of positive axillary status (ypN+) after PST among these patients based on clinical and pathological parameters.
Methods:Patients converting from cN+ to ycN0 due to PST included in a prospective study (SENTINA, Arm C) were included. Univariate and multivariate analyses were carried out to evaluate the association between 14 clinical/pathological parameters and pathological axillary status (ypN0 vs ypN+) using logistic regression models. Model accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were assessed applying leave-one-out cross-validation (LOOCV) and ROC analyses. Different cut-points were evaluated. Calculations were performed using the SAS Software (Version 9.4, SAS Institute Inc., Cary, NC, USA.).
Results: Arm C contained 553 patients, 369 patients were evaluable with respect to the above parameters. Univariate analyses revealed a significant association between pathological axillary status and ER status (odds ratio (OR) 4.05, 95% confidence interval (95%CI) 2.81-5.83), PR status (OR 3.07, 95%CI 2.16-4.36), multifocality (OR 2.37, 95%CI 1.57-3.58), lymphovascular invasion (OR 8.61, 95%CI 5.12-14.46), detection of a SLN after NAT (OR .56, 95%CI .36-.87), detection method (IHC vs routine: OR .46, 95%CI .27-.78; IHC vs serial HE: OR .72, 95%CI .49-1.07; serial hematoxylin eosin (HE) vs routine: OR .639, 95%CI .39-1.04), clinical tumor size (OR 1.051, 95%CI 1.03-1.07) and pCR-status in the breast (ypT0 and ypTis vs others, OR .11, 95%CI .08-.17). A multivariate model was fitted including significant clinical parameters. Stepwise backward variable selection was carried out resulting in a model including ER status (OR 3.81, 95%CI 2.25-6.44), multifocality (OR 2.22, 95%CI 1.26-3.92), LVI (OR 9.16, 95%CI 4.68-17.90), detection of a SLN after NAT (OR .50, 95%CI .26-.95) and clinical tumor size (OR 1.03, 95%CI 1.01-1.06). In LOOCV, this model demonstrated an accuracy of 73% (sensitivity 73%, specificity 72%, PPV 75%, NPV 70%) using .5 as cut-off. Based on the performed ROC analysis an area under the curve (AUC) of 0.81 was calculated.
Conclusion: A model using ER status, multifocality, LVI, detection of a SLN after NAT and clinical tumor size was built to predict pathological axillary status (ypN+) with a high accuracy. If successfully validated based upon an independent dataset, this nomogram could allow advising patients for / against axillary surgery in case of clinical axillary conversion after NAT.
Citation Format: Liedtke C, Kolberg H-C, Kerschke L, Goerlich D, Bauerfeind I, Fehm T, Fleige B, Hauschild M, Helms G, Lebeau A, Schmatloch S, Schrenk P, Schwentner L, Staebler A, von Minckwitz G, Loibl S, Untch M, Kuehn T. Development and validation of a nomogram predicting pathological axillary status (ypN0 vs. ypN+) in a subgroup of patients converting from cN+ to ycN0 through neoadjuvant therapy (NAT) – A transSENTINA substudy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-13-06.
Collapse
Affiliation(s)
- C Liedtke
- University Hospital Schleswig-Holstein / Campus Luebeck, Germany; Marien-Hospital Bottrop, Germany; University Hospital Münster, Germany; Klinikum Landshut, Germany; University Hospital Duesseldorf, Germany; Helios-Klinikum Berlin-Buch, Germany; Spital Rheinfelden, Switzerland; University Hospital Tuebingen, Germany; University Hospital Hamburg-Eppendorf, Germany; Hospital Kassel, Germany; AKH Linz, Germany; University Hospital Ulm, Germany; German Breast Group, Germany; Klinikum Esslingen, Germany
| | - H-C Kolberg
- University Hospital Schleswig-Holstein / Campus Luebeck, Germany; Marien-Hospital Bottrop, Germany; University Hospital Münster, Germany; Klinikum Landshut, Germany; University Hospital Duesseldorf, Germany; Helios-Klinikum Berlin-Buch, Germany; Spital Rheinfelden, Switzerland; University Hospital Tuebingen, Germany; University Hospital Hamburg-Eppendorf, Germany; Hospital Kassel, Germany; AKH Linz, Germany; University Hospital Ulm, Germany; German Breast Group, Germany; Klinikum Esslingen, Germany
| | - L Kerschke
- University Hospital Schleswig-Holstein / Campus Luebeck, Germany; Marien-Hospital Bottrop, Germany; University Hospital Münster, Germany; Klinikum Landshut, Germany; University Hospital Duesseldorf, Germany; Helios-Klinikum Berlin-Buch, Germany; Spital Rheinfelden, Switzerland; University Hospital Tuebingen, Germany; University Hospital Hamburg-Eppendorf, Germany; Hospital Kassel, Germany; AKH Linz, Germany; University Hospital Ulm, Germany; German Breast Group, Germany; Klinikum Esslingen, Germany
| | - D Goerlich
- University Hospital Schleswig-Holstein / Campus Luebeck, Germany; Marien-Hospital Bottrop, Germany; University Hospital Münster, Germany; Klinikum Landshut, Germany; University Hospital Duesseldorf, Germany; Helios-Klinikum Berlin-Buch, Germany; Spital Rheinfelden, Switzerland; University Hospital Tuebingen, Germany; University Hospital Hamburg-Eppendorf, Germany; Hospital Kassel, Germany; AKH Linz, Germany; University Hospital Ulm, Germany; German Breast Group, Germany; Klinikum Esslingen, Germany
| | - I Bauerfeind
- University Hospital Schleswig-Holstein / Campus Luebeck, Germany; Marien-Hospital Bottrop, Germany; University Hospital Münster, Germany; Klinikum Landshut, Germany; University Hospital Duesseldorf, Germany; Helios-Klinikum Berlin-Buch, Germany; Spital Rheinfelden, Switzerland; University Hospital Tuebingen, Germany; University Hospital Hamburg-Eppendorf, Germany; Hospital Kassel, Germany; AKH Linz, Germany; University Hospital Ulm, Germany; German Breast Group, Germany; Klinikum Esslingen, Germany
| | - T Fehm
- University Hospital Schleswig-Holstein / Campus Luebeck, Germany; Marien-Hospital Bottrop, Germany; University Hospital Münster, Germany; Klinikum Landshut, Germany; University Hospital Duesseldorf, Germany; Helios-Klinikum Berlin-Buch, Germany; Spital Rheinfelden, Switzerland; University Hospital Tuebingen, Germany; University Hospital Hamburg-Eppendorf, Germany; Hospital Kassel, Germany; AKH Linz, Germany; University Hospital Ulm, Germany; German Breast Group, Germany; Klinikum Esslingen, Germany
| | - B Fleige
- University Hospital Schleswig-Holstein / Campus Luebeck, Germany; Marien-Hospital Bottrop, Germany; University Hospital Münster, Germany; Klinikum Landshut, Germany; University Hospital Duesseldorf, Germany; Helios-Klinikum Berlin-Buch, Germany; Spital Rheinfelden, Switzerland; University Hospital Tuebingen, Germany; University Hospital Hamburg-Eppendorf, Germany; Hospital Kassel, Germany; AKH Linz, Germany; University Hospital Ulm, Germany; German Breast Group, Germany; Klinikum Esslingen, Germany
| | - M Hauschild
- University Hospital Schleswig-Holstein / Campus Luebeck, Germany; Marien-Hospital Bottrop, Germany; University Hospital Münster, Germany; Klinikum Landshut, Germany; University Hospital Duesseldorf, Germany; Helios-Klinikum Berlin-Buch, Germany; Spital Rheinfelden, Switzerland; University Hospital Tuebingen, Germany; University Hospital Hamburg-Eppendorf, Germany; Hospital Kassel, Germany; AKH Linz, Germany; University Hospital Ulm, Germany; German Breast Group, Germany; Klinikum Esslingen, Germany
| | - G Helms
- University Hospital Schleswig-Holstein / Campus Luebeck, Germany; Marien-Hospital Bottrop, Germany; University Hospital Münster, Germany; Klinikum Landshut, Germany; University Hospital Duesseldorf, Germany; Helios-Klinikum Berlin-Buch, Germany; Spital Rheinfelden, Switzerland; University Hospital Tuebingen, Germany; University Hospital Hamburg-Eppendorf, Germany; Hospital Kassel, Germany; AKH Linz, Germany; University Hospital Ulm, Germany; German Breast Group, Germany; Klinikum Esslingen, Germany
| | - A Lebeau
- University Hospital Schleswig-Holstein / Campus Luebeck, Germany; Marien-Hospital Bottrop, Germany; University Hospital Münster, Germany; Klinikum Landshut, Germany; University Hospital Duesseldorf, Germany; Helios-Klinikum Berlin-Buch, Germany; Spital Rheinfelden, Switzerland; University Hospital Tuebingen, Germany; University Hospital Hamburg-Eppendorf, Germany; Hospital Kassel, Germany; AKH Linz, Germany; University Hospital Ulm, Germany; German Breast Group, Germany; Klinikum Esslingen, Germany
| | - S Schmatloch
- University Hospital Schleswig-Holstein / Campus Luebeck, Germany; Marien-Hospital Bottrop, Germany; University Hospital Münster, Germany; Klinikum Landshut, Germany; University Hospital Duesseldorf, Germany; Helios-Klinikum Berlin-Buch, Germany; Spital Rheinfelden, Switzerland; University Hospital Tuebingen, Germany; University Hospital Hamburg-Eppendorf, Germany; Hospital Kassel, Germany; AKH Linz, Germany; University Hospital Ulm, Germany; German Breast Group, Germany; Klinikum Esslingen, Germany
| | - P Schrenk
- University Hospital Schleswig-Holstein / Campus Luebeck, Germany; Marien-Hospital Bottrop, Germany; University Hospital Münster, Germany; Klinikum Landshut, Germany; University Hospital Duesseldorf, Germany; Helios-Klinikum Berlin-Buch, Germany; Spital Rheinfelden, Switzerland; University Hospital Tuebingen, Germany; University Hospital Hamburg-Eppendorf, Germany; Hospital Kassel, Germany; AKH Linz, Germany; University Hospital Ulm, Germany; German Breast Group, Germany; Klinikum Esslingen, Germany
| | - L Schwentner
- University Hospital Schleswig-Holstein / Campus Luebeck, Germany; Marien-Hospital Bottrop, Germany; University Hospital Münster, Germany; Klinikum Landshut, Germany; University Hospital Duesseldorf, Germany; Helios-Klinikum Berlin-Buch, Germany; Spital Rheinfelden, Switzerland; University Hospital Tuebingen, Germany; University Hospital Hamburg-Eppendorf, Germany; Hospital Kassel, Germany; AKH Linz, Germany; University Hospital Ulm, Germany; German Breast Group, Germany; Klinikum Esslingen, Germany
| | - A Staebler
- University Hospital Schleswig-Holstein / Campus Luebeck, Germany; Marien-Hospital Bottrop, Germany; University Hospital Münster, Germany; Klinikum Landshut, Germany; University Hospital Duesseldorf, Germany; Helios-Klinikum Berlin-Buch, Germany; Spital Rheinfelden, Switzerland; University Hospital Tuebingen, Germany; University Hospital Hamburg-Eppendorf, Germany; Hospital Kassel, Germany; AKH Linz, Germany; University Hospital Ulm, Germany; German Breast Group, Germany; Klinikum Esslingen, Germany
| | - G von Minckwitz
- University Hospital Schleswig-Holstein / Campus Luebeck, Germany; Marien-Hospital Bottrop, Germany; University Hospital Münster, Germany; Klinikum Landshut, Germany; University Hospital Duesseldorf, Germany; Helios-Klinikum Berlin-Buch, Germany; Spital Rheinfelden, Switzerland; University Hospital Tuebingen, Germany; University Hospital Hamburg-Eppendorf, Germany; Hospital Kassel, Germany; AKH Linz, Germany; University Hospital Ulm, Germany; German Breast Group, Germany; Klinikum Esslingen, Germany
| | - S Loibl
- University Hospital Schleswig-Holstein / Campus Luebeck, Germany; Marien-Hospital Bottrop, Germany; University Hospital Münster, Germany; Klinikum Landshut, Germany; University Hospital Duesseldorf, Germany; Helios-Klinikum Berlin-Buch, Germany; Spital Rheinfelden, Switzerland; University Hospital Tuebingen, Germany; University Hospital Hamburg-Eppendorf, Germany; Hospital Kassel, Germany; AKH Linz, Germany; University Hospital Ulm, Germany; German Breast Group, Germany; Klinikum Esslingen, Germany
| | - M Untch
- University Hospital Schleswig-Holstein / Campus Luebeck, Germany; Marien-Hospital Bottrop, Germany; University Hospital Münster, Germany; Klinikum Landshut, Germany; University Hospital Duesseldorf, Germany; Helios-Klinikum Berlin-Buch, Germany; Spital Rheinfelden, Switzerland; University Hospital Tuebingen, Germany; University Hospital Hamburg-Eppendorf, Germany; Hospital Kassel, Germany; AKH Linz, Germany; University Hospital Ulm, Germany; German Breast Group, Germany; Klinikum Esslingen, Germany
| | - T Kuehn
- University Hospital Schleswig-Holstein / Campus Luebeck, Germany; Marien-Hospital Bottrop, Germany; University Hospital Münster, Germany; Klinikum Landshut, Germany; University Hospital Duesseldorf, Germany; Helios-Klinikum Berlin-Buch, Germany; Spital Rheinfelden, Switzerland; University Hospital Tuebingen, Germany; University Hospital Hamburg-Eppendorf, Germany; Hospital Kassel, Germany; AKH Linz, Germany; University Hospital Ulm, Germany; German Breast Group, Germany; Klinikum Esslingen, Germany
| |
Collapse
|
16
|
Gschwantler-Kaulich E, Schrenk P, Bjelic-Radisic V, Unterrieder K, Leser C, Fink-Retter A, Salama M, Singer C. Mesh versus acellular dermal matrix in immediate implant based breast reconstruction – a prospective randomized trial. Eur J Cancer 2017. [DOI: 10.1016/s0959-8049(17)30176-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
17
|
Schwentner L, Helms G, Nekljudova V, Ataseven B, Bauerfeind I, Ditsch N, Fehm T, Fleige B, Hauschild M, Heil J, Kümmel S, Lebeau A, Schmatloch S, Schrenk P, Staebler A, Loibl S, Untch M, Von Minckwitz G, Liedtke C, Kühn T. Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy – Results from the multi-center SENTINA trial. Breast 2017; 31:202-207. [DOI: 10.1016/j.breast.2016.11.012] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2016] [Revised: 11/10/2016] [Accepted: 11/11/2016] [Indexed: 10/20/2022] Open
|
18
|
Schwentner L, Helms G, Nekljudova V, Ataseven B, Bauerfeind I, Ditsch N, Fehm TN, Fleige B, Hauschild M, Heil J, Kümmel S, Lebeau A, Liedtke C, Loibl S, Schmatloch S, Schrenk P, Staebler A, Untch M, Von Minckwitz G, Kühn T. Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy: Results from the prospective multi-center SENTINA trial. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.1054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Lukas Schwentner
- Department of Gynecology and Obstetrics University Ulm, Ulm, Germany
| | - Gisela Helms
- Universitatsklinikum Tubingen, Tubingen, Germany
| | | | - Beyhan Ataseven
- Department of Gynecology, Klinikum Essen Mitte, Essen, Germany
| | - Ingo Bauerfeind
- Department of Obstetrics and Gynecology & Interdisciplinary Breast Cancer Center, Klinikum Landshut, Landshut, Germany
| | - Nina Ditsch
- Ludwig Maximilians University Munich, Munich, Germany
| | | | | | | | - Joerg Heil
- Department of Obstetrics and Gynaecology, University of Heidelberg,, Heidelberg, Germany
| | - Sherko Kümmel
- Department of Senology / Breast Care Center, Kliniken Essen Mitte, Essen, Germany
| | - Annette Lebeau
- Institut für Pathologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr, Hamburg, Germany
| | - Cornelia Liedtke
- University of Schleswig-Holstein Campus Luebeck, Luebeck, Germany
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
Background: Different types of acellular dermal, synthetic and biological matrices have been used in connection with immediate implant-based breast reconstruction. Patients & methods: A new long-term absorbable surgical matrix, TIGR® Matrix mesh was used in a total of 29 patients undergoing a total of 37 mastectomies and immediate reconstruction. Results: Early postoperative results showed no adverse reactions to the mesh and a good integration into the tissue. Conclusion: It may therefore constitute an alternative to acellular, dermal or other synthetic matrices currently available.
Collapse
Affiliation(s)
- Peter Schrenk
- Breast Cancer Center, Kepler University Clinic, Linz, Austria
| |
Collapse
|
20
|
Gschwantler-Kaulich D, Schrenk P, Bjelic-Radisic V, Unterrieder K, Leser C, Fink-Retter A, Salama M, Singer C. Mesh versus acellular dermal matrix in immediate implant-based breast reconstruction - A prospective randomized trial. Eur J Surg Oncol 2016; 42:665-71. [PMID: 26947961 DOI: 10.1016/j.ejso.2016.02.007] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Revised: 01/21/2016] [Accepted: 02/02/2016] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND Comparative studies on the use of meshes and acellular dermal matrices (ADM) in implant-based breast reconstruction (IBBR) have not yet been performed. METHODS This prospective, randomized, controlled, multicenter pilot study was performed at four Austrian breast cancer centers. Fifty patients with oncologic or prophylactic indication for mastectomy and IBBR were randomized to immediate IBBR with either an ADM (Protexa(®)) or a titanized mesh (TiLOOP(®) Bra). Complications, failed reconstruction, cosmetic outcome, patients' quality of life and the thickness of the overlying tissue were recorded immediately postoperatively and 3 and 6 months after surgery. RESULTS 48 patients participated in the study (Protexa(®) group: 23; TiLOOP(®) Bra group: 25 patients). The overall complication rate was 31.25% with similar rates in both groups (Protexa(®) group: 9 versus TiLOOP(®) Bra group: 6; p = 0.188). There was a higher incidence of severe complications leading to failed reconstructions with implant loss in the Protexa(®) group than in the TiLOOP(®) Bra group (7 versus 2; p < 0.0001). An inverted T-incision technique led to significantly more complications and reconstructive failure with Protexa(®) (p = 0.037, p = 0.012, respectively). There were no significant differences in patients' satisfaction with cosmetic results (p = 0.632), but surgeons and external specialists graded significantly better outcomes with TiLOOP(®) Bra (p = 0.034, p = 0.032). CONCLUSION This pilot study showed use of TiLOOP(®) Bra or Protexa(®) in IBBR is feasible leading to good cosmetic outcomes and high patient satisfaction. To validate the higher failure rates in the Protexa(®) group, data from a larger trial are required. NCT02562170.
Collapse
Affiliation(s)
- D Gschwantler-Kaulich
- Medical University of Vienna, Breast Cancer Center, Department of Gynaecological Oncology, Waehringer Guertel 18-20, 1090 Vienna, Austria.
| | - P Schrenk
- AKH Linz Breast Cancer Center, Krankenhausstrasse 9, 4021 Linz, Austria
| | - V Bjelic-Radisic
- Medical University of Graz, Department of Gynaecology, Auenbruggerplatz 1, 8036 Graz, Austria
| | - K Unterrieder
- Private Hospital Villach, Breast Cancer Center, Department of Gynaecology, Dr.-Walter-Hochsteiner-Straße 4, 9504 Villach, Austria
| | - C Leser
- Medical University of Vienna, Breast Cancer Center, Department of Gynaecological Oncology, Waehringer Guertel 18-20, 1090 Vienna, Austria
| | - A Fink-Retter
- Medical University of Vienna, Breast Cancer Center, Department of Gynaecological Oncology, Waehringer Guertel 18-20, 1090 Vienna, Austria
| | - M Salama
- Otto Wagner Hospital, Department of Surgery, Baumgartner Hoehe 1, 1140 Vienna, Austria
| | - C Singer
- Medical University of Vienna, Breast Cancer Center, Department of Gynaecological Oncology, Waehringer Guertel 18-20, 1090 Vienna, Austria
| |
Collapse
|
21
|
Schermann C, Zurl B, Regitnig P, Moinfar F, Symmans F, Bjelic-Radisic V, Schrenk P, Peintinger F. Agreement Between Predicted Response by Imaging Methods and Pathological Response by RCB in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu068.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schmatloch S, Schrenk P, Staebler A, Untch M. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013; 14:609-18. [PMID: 23683750 DOI: 10.1016/s1470-2045(13)70166-9] [Citation(s) in RCA: 867] [Impact Index Per Article: 78.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND The optimum timing of sentinel-lymph-node biopsy for breast cancer patients treated with neoadjuvant chemotherapy is uncertain. The SENTINA (SENTinel NeoAdjuvant) study was designed to evaluate a specific algorithm for timing of a standardised sentinel-lymph-node biopsy procedure in patients who undergo neoadjuvant chemotherapy. METHODS SENTINA is a four-arm, prospective, multicentre cohort study undertaken at 103 institutions in Germany and Austria. Women with breast cancer who were scheduled for neoadjuvant chemotherapy were enrolled into the study. Patients with clinically node-negative disease (cN0) underwent sentinel-lymph-node biopsy before neoadjuvant chemotherapy (arm A). If the sentinel node was positive (pN1), a second sentinel-lymph-node biopsy procedure was done after neoadjuvant chemotherapy (arm B). Women with clinically node-positive disease (cN+) received neoadjuvant chemotherapy. Those who converted to clinically node-negative disease after chemotherapy (ycN0; arm C) were treated with sentinel-lymph-node biopsy and axillary dissection. Only patients whose clinical nodal status remained positive (ycN1) underwent axillary dissection without sentinel-lymph-node biopsy (arm D). The primary endpoint was accuracy (false-negative rate) of sentinel-lymph-node biopsy after neoadjuvant chemotherapy for patients who converted from cN1 to ycN0 disease during neoadjuvant chemotherapy (arm C). Secondary endpoints included comparison of the detection rate of sentinel-lymph-node biopsy before and after neoadjuvant chemotherapy, and also the false-negative rate and detection rate of sentinel-lymph-node biopsy after removal of the sentinel lymph node. Analyses were done according to treatment received (per protocol). FINDINGS Of 1737 patients who received treatment, 1022 women underwent sentinel-lymph-node biopsy before neoadjuvant chemotherapy (arms A and B), with a detection rate of 99.1% (95% CI 98.3-99.6; 1013 of 1022). In patients who converted after neoadjuvant chemotherapy from cN+ to ycN0 (arm C), the detection rate was 80.1% (95% CI 76.6-83.2; 474 of 592) and false-negative rate was 14.2% (95% CI 9.9-19.4; 32 of 226). The false-negative rate was 24.3% (17 of 70) for women who had one node removed and 18.5% (10 of 54) for those who had two sentinel nodes removed (arm C). In patients who had a second sentinel-lymph-node biopsy procedure after neoadjuvant chemotherapy (arm B), the detection rate was 60.8% (95% CI 55.6-65.9; 219 of 360) and the false-negative rate was 51.6% (95% CI 38.7-64.2; 33 of 64). INTERPRETATION Sentinel-lymph-node biopsy is a reliable diagnostic method before neoadjuvant chemotherapy. After systemic treatment or early sentinel-lymph-node biopsy, the procedure has a lower detection rate and a higher false-negative rate compared with sentinel-lymph-node biopsy done before neoadjuvant chemotherapy. These limitations should be considered if biopsy is planned after neoadjuvant chemotherapy. FUNDING Brustkrebs Deutschland, German Society for Senology, German Breast Group.
Collapse
Affiliation(s)
- Thorsten Kuehn
- Interdisciplinary Breast Centre, Department of Gynaecology and Obstetrics, Klinikum Esslingen, Esslingen, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Hubalek M, Bartsch R, Gnant M, Kapp KS, Lang A, Lax S, Lukas P, Neunteufel W, Pristauz G, Reitsamer R, Sandbichler P, Schrenk P, Singer C, Tamussino K, Tschmelitsch J, Zeimet AG, Marth C. Axillary Dissection in the Case of Positive Sentinel Lymph Nodes: Results of the Innsbruck Consensus Conference. Geburtshilfe Frauenheilkd 2012; 72:293-298. [PMID: 25284834 DOI: 10.1055/s-0031-1298441] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Abstract
The prognosis of breast cancer is most heavily influenced by the status of the axillary nodes. Until a few years ago, this knowledge was gained through radical axillary lymph node clearance. In the meantime, sentinel lymph node clearance has become an established part of the surgical treatment of breast cancer. With the development of this procedure, the morbidity caused by axillary dissection has been reduced significantly. Although comprehensive prospective, randomised data regarding the safe use of the sentinel concept are only now available, the focus currently, however, is on the question of whether in the case of positive sentinel lymph nodes, an axillary dissection can be done away with altogether without having any negative impact on the risk of loco-regional recurrence or on progression-free survival and overall survival. The results of the American ACOSOG-Z001 study have changed the fundamental perspective of this. In this study on the advantages of axillary dissection following the confirmation of tumour tissue in the sentinel lymph nodes, there were no statistically significant advantages from axillary dissection for women with a favourable overall risk profile who had received radiotherapy and systemic therapy. If this concept takes hold, the surgical treatment of node-positive breast cancer, at least in the axilla, would be reduced to a minimum, and the focus of treatment would in future lie more on the systemic treatment of this condition. As part of an interdisciplinary consensus meeting, a standardised approach for Austria with regard to this question was decided upon.
Collapse
Affiliation(s)
- M Hubalek
- Department of Women's Health, Clin. Dept. of Gynaecology and Obstetrics, Innsbruck, Austria
| | - R Bartsch
- University Department of Internal Medicine I, Breast Health Centre MUW/AKH, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria
| | - M Gnant
- University Department of Surgery, Breast Health Centre MUW/AKH, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria
| | - K S Kapp
- University Department of Radiotherapy/Radio-Oncology, Graz, Austria
| | - A Lang
- Feldkirch State Hospital, Dept. of Internal Medicine, Haematology and Medical Oncology, Feldkirch, Austria
| | - S Lax
- Graz West State Hospital, Institute of Pathology, Graz, Austria
| | - P Lukas
- University Department of Radiotherapy/Radio-Oncology, Innsbruck, Austria
| | - W Neunteufel
- Dornbirn Hospital, Department of Gynaecology and Obstetrics, Dornbirn, Austria
| | - G Pristauz
- University Department of Gynaecology and Obstetrics, Clinical Department of Gynaecology, Graz, Austria
| | - R Reitsamer
- St. Johanns-Spital/State Women's Hospital, University Department of Specialist Gynaecology, Salzburg, Austria
| | - P Sandbichler
- St.Vinzenz Hospital, Department of Surgery, Zams, Austria
| | - P Schrenk
- Linz City Hospital, Dept. of Surgery II, Breast Competence Centre, Linz, Austria
| | - C Singer
- Clinical Department of General Gynaecology and Gynaecological Oncology, Medical University of Vienna, Vienna, Austria
| | - K Tamussino
- University Department of Gynaecology and Obstetrics, Clinical Department of Gynaecology, Graz, Austria
| | - J Tschmelitsch
- Hospital of the Merciful Brothers, Surgical Department, St. Veit/Glan, Austria
| | - A G Zeimet
- Department of Women's Health, Clin. Dept. of Gynaecology and Obstetrics, Innsbruck, Austria
| | - C Marth
- Department of Women's Health, Clin. Dept. of Gynaecology and Obstetrics, Innsbruck, Austria
| |
Collapse
|
24
|
Kühn T, Bauerfeind I, Fehm T, Helms G, Lebeau A, Liedtke C, Mai M, Nekljudova V, Schrenk P, Untch M. 6 Impact of Neoadjuvant Systemic Treatment and Prior Surgery On Sentinel Lymph Node Detection – Results From the Prospective German Multiinstitutional SENTINa Trial. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70074-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
25
|
Woelfl S, Bogner S, Broinger G, Bergmayr A, Pühringer K, Schrenk P, Sir A. 170 Intra-operative Use of One Step Nucleic Acid Amplification (OSNA) for Whole Sentinel Lymph Node Analysis in Breast Cancer Patients. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70238-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
26
|
Thorsten K, Bauerfeind I, Fehm T, Fleige B, Gisela H, Lebeau A, Liedtke C, Mai M, Von Minckwitz G, Schrenk P, Staebler A, Untch M. Abstract P1-01-04: Axillary Intervention in Patients Undergoing Neoadjuvant Therapy (NST) — First Results from the SENTINA Study. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p1-01-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The optimal scheduling for sentinel lymph node biopsy (SLNB) among patients with breast cancer undergoing neoadjuvant systemic therapy (NST) is unclear. SENTINA-study is the first prospective multicenter trial that systematically examines the feasibilty and reliability of SLNB prior to and after (NST). Here we present results of a first exploratory analysis by examining distribution of N-stages in the different treatment arms and correlating the axillary status with the type of breast surgery (breast conserving therapy [BCT] vs mastectomy [ME]).
Methods: The SENTINA study is a four-arm multicenter (n= XXX) observation study. Patients will be stratified based on their clinical lymph node status prior to treatment. If the lymph node status is clinically negative SLNB is performed before NST. Patients with a negative SLN will undergo no further axillary surgery (Arm A), whereas patients with a positive SLN will be treated with sentinel-node-guided axillary dissection (SLNB-AD) after NST (Arm B). If the lymph node is clinically positive upon initial presentation, patients will undergo NST prior to any axillary intervention. If patients convert to a clinically negative lymph node status through NST they will undergo SLNB-AD (ARM C). Patients with persistent positive nodes or whose tumors progress under NST undergo primary axillary dissection (Arm D). Clinically node positive patients will be endcouraged to undergo FNA to confirm their lymph node status. A total of 1508 patients in the entire study will be needed to calculate the false-negative rate in this group with a one-sided 95% confidence interval not exceeding 10%.
Results: 873 patients have been accrued into SENTINA until may 31th 2010, 523 (59,9%) have completed their treatment. 180 (34,4%) women have been treated in Arm A and 117 (22,4%) in Arm B. In 170 (32,5%) patients the clinical axillary status converted from a clinical positive to a clinical negative status (Arm C). In 65 pts (12,4%) the axillary status remained positive or the tumor progressed under NCHT (Arm D). BCT rates in Arm A-D were 88.3%, 75.2%, 61.8% and 22.2% respectively.
Conclusion: First results of the SENTINA study show a strong correlation between the axillary status and the type of breast surgery in patients, who are treated with NST. Importantly, we demonstrate that the clinical assessment of the axillary status is unprecise. There is an urgent need to optimize the tailoring of axillary intervention in the setting of NST
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-01-04.
Collapse
Affiliation(s)
- K Thorsten
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - I Bauerfeind
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - T Fehm
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - B Fleige
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - H Gisela
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - A Lebeau
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - C Liedtke
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - M Mai
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - G Von Minckwitz
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - P Schrenk
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - A Staebler
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| | - M. Untch
- Klinikum Esslingen, Baden Württemberg, Germany; Klinikum Landshut, Bavarian, Germany; Universitaetsklinikum, Tuebingen, Germany; Fleige; Universitätsklinikum Eppendorf; Universitätsklinikum Münster, Germany; HELIOS Klinikum Berlin-Buch, Berlin, Germany; University Hospital Tübingen, Germany
| |
Collapse
|
27
|
Haid A, Kühn T, Goyal A, Tausch C, Peintinger F, Schrenk P, Gallowitsch H. Sentinel Node Biopsy in Breast Cancer: Clinical Implication – Standard of Care – Fututre Prospects. Breast Care (Basel) 2009; 4:195-202. [DOI: 10.1159/000218329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
28
|
Schrenk P, Tausch C, Huemer G. Superior pedicle mammaplasty with a deepithelialized inferior breast pedicle for immediate reconstruction of quadrantectomy defects in patients with breast cancer or tissue defects. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)70859-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
29
|
Wagner E, Schrenk P, Huemer GM, Sir A, Schreiner M, Wayand W. Central quadrantectomy with resection of the nipple-areola complex compared with mastectomy in patients with retroareolar breast cancer. Breast J 2007; 13:557-63. [PMID: 17983395 DOI: 10.1111/j.1524-4741.2007.00492.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Appropriate surgery in women with retroareolar breast cancer should allow resection of the cancer with wide free margins and an acceptable cosmetic result. The aim of this study was to compare breast conservation surgery (BCS) to mastectomy for treatment of retroareolar breast cancer. In a prospective nonrandomized study, 69 women with retroareolar breast cancers underwent either central quadrantectomy (n=33) with complete removal of the nipple-areola complex or mastectomy (n=36). Two of 33 (6%) patients scheduled for BCS had a secondary mastectomy and immediate reconstruction due to involved margins. After a median follow-up of 42 month (range 17-99 months) in the BCS group and 43 months (range 16-118 months) in the mastectomy group local and regional recurrences as well as systemic disease were comparable between both groups. The postoperative cosmetic result after BCS as evaluated by the patients was rated as excellent in 80% and good in 20% with no poor result. BCS followed by radiation therapy is a feasible alternative to mastectomy in patients with retroareolar breast cancer.
Collapse
Affiliation(s)
- Elke Wagner
- Second Department of Surgery--Ludwig Boltzmann Institute for Surgical Laparoscopy, AKH Linz, Austria
| | | | | | | | | | | |
Collapse
|
30
|
Konstantiniuk P, Schrenk P, Reitsamer R, Koeberle-Wuehrer R, Tausch C, Roka S, Riedl O, Poestlberger S, Hecke D, Janauer M, Haid A. A nonrandomized follow-up comparison between standard axillary node dissection and sentinel node biopsy in breast cancer. Breast 2007; 16:520-6. [PMID: 17566737 DOI: 10.1016/j.breast.2007.04.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2007] [Accepted: 04/02/2007] [Indexed: 11/17/2022] Open
Abstract
INTRODUCTION In many countries sentinel node biopsy (SNB) has become the standard of care in breast cancer based on a large number of observational studies but without results from prospective randomized trials. The goal of our study was to evaluate the oncological safety of the SNB in breast cancer in a multicenter, nonrandomized setting with comparable groups. PATIENTS AND METHODS Between 1996/05 and 2004/11, 2942 patients from 14 departments in Austria with unicentric, unilateral, invasive disease without neoadjuvant therapy were collected in a database. The recommendations of the Austrian Sentinel Node Study Group were to complete a training period (phase I) with 50 cases of SNB followed by axillary lymph node dissection (ALND) to prove a detection rate of > or = 90% and a false-negative rate of < or = 5%. In the executing period (phase II), SNB was followed by ALND only if the sentinel node (SN) contained metastases. We compared the results on disease-free survival, local recurrence rates, distant recurrence rates and overall survival of both groups. Cases from phases I and II generated groups I (n=671) and 2 (n=2271 cases), respectively. RESULTS Overall mean follow-up time: 34.41 months. CONCLUSION SNB followed by ALND only in cases with metastases in the SN is a safe procedure and at least equal to ALND in all cases.
Collapse
|
31
|
Abstract
BACKGROUND Operative techniques for oncoplastic reconstruction combine oncologic extirpation of the tumor with immediate reconstruction of breast shape and symmetry. These techniques are increasingly being used for breast-conservation therapy of centrally located breast carcinomas. The goal of this study was to provide an overview of the various surgical options for oncoplastic treatment of central breast carcinomas. METHODS From September of 1998 through January of 2005, 31 women (median age, 61 years) were treated for 32 centrally located breast carcinomas by breast-conserving therapy. There were 27 invasive tumors (median size, 13.5 mm), and five patients had ductal carcinoma in situ (median size, 39.6 mm). One patient received chemotherapy preoperatively for tumor reduction. A total of 11 patients had a positive lymph-node status, and 21 patients had a free sentinel node. RESULTS The various surgical techniques included a central lumpectomy with direct closure (n = 6), central lumpectomy with inverted T-closure (n = 2), a circumareolar, Benelli-type closure (n = 2), a modified Grisotti-flap closure (n = 9), and a mammaplasty-type closure with an inferiorly based pedicle (n = 13). In 27 patients, a contralateral procedure was undertaken (bilateral carcinoma or symmetrizing mammaplasty). Two patients required a secondary mastectomy because of ductal carcinoma in situ with positive surgical margins in the final histology. They were treated by immediate reconstruction with an implant and a pedicled myocutaneous latissimus dorsi flap, respectively. In a median follow-up of 33.8 months, there were no local recurrences in the remaining breast or axilla, but two patients developed distant metastases. CONCLUSIONS Breast carcinoma of small size that occurs in a central location can be safely treated oncologically by breast conservation therapy. The use of various oncoplastic techniques yields very satisfactory aesthetic results.
Collapse
Affiliation(s)
- Georg M Huemer
- Linz, Austria From the Department of Plastic Surgery, Sisters of Mercy Hospital; Second Surgical Department, Allgemeines Krankenhaus; Ludwig-Boltzmann Institut für operative Laparoskopie; and Mikrochirurgisches Ausbildungs- und Forschungszentrum (maz)
| | | | | | | | | |
Collapse
|
32
|
Sir A, Schrenk P, Shebl O, Tews G. Das Schwangerschaft-assoziierte-Mammakarzinom – Ein Update anhand zweier Case Reports. Geburtshilfe Frauenheilkd 2007. [DOI: 10.1055/s-2007-983518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
33
|
Schrenk P, Wölfl S, Bogner S, Huemer G, Wayand W. Symmetrization reduction mammaplasty combined with sentinel node biopsy in patients operated for contralateral breast cancer (J. Surg. Oncol. 2006;94:9–15). J Surg Oncol 2006. [DOI: 10.1002/jso.20682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
34
|
Schrenk P, Wölfl S, Bogner S, Huemer GM, Huemer G, Wayand W. Symmetrization reduction mammaplasty combined with sentinel node biopsy in patients operated for contralateral breast cancer. J Surg Oncol 2006; 94:9-15. [PMID: 16788937 DOI: 10.1002/jso.20542] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
BACKGROUND AND OBJECTIVES Occult invasive cancer found in reduction mammaplasty specimen in the contralateral breast in breast cancer patients requires axillary lymph node dissection (ALND) to assess the lymph node status. Routine Sentinel node (SN) biopsy in these patients may avoid secondary ALND when an occult cancer is found and the SN is negative in the permanent histological examination. METHODS One hundred sixty-nine breast cancer patients underwent contralateral reduction mammaplasty for symmetrization and with SN biopsy of the non-cancer breast. SN mapping was done using a vital blue dye alone (n = 136) or in combination with a radiocolloid (n = 33). RESULTS A mean number of 1.4 SNs (range 1-3 SNs) was identified in 158 of 169 patients (identification rate 93.5%). One of 158 patients revealed a positive SN but no tumor was found in the reduction mammaplasty/mastectomy specimen, whereas the SN was negative in 157 patients. Histological examination of the 169 reduction mammaplasty specimen revealed 5 occult invasive cancers and 4 patients with high grade DCIS but due to a negative SN biopsy the patients were spared a secondary ALND. CONCLUSION The small number of patients with occult contralateral cancers may not warrant routine SN mapping in patients scheduled for contralateral reduction mammaplasty.
Collapse
MESH Headings
- Adult
- Aged
- Axilla
- Breast Neoplasms/pathology
- Breast Neoplasms/surgery
- Carcinoma in Situ/pathology
- Carcinoma in Situ/surgery
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Ductal, Breast/secondary
- Carcinoma, Ductal, Breast/surgery
- Carcinoma, Intraductal, Noninfiltrating/pathology
- Carcinoma, Intraductal, Noninfiltrating/secondary
- Carcinoma, Intraductal, Noninfiltrating/surgery
- Female
- Humans
- Lymph Node Excision
- Lymph Nodes/pathology
- Lymphatic Metastasis
- Mammaplasty/methods
- Middle Aged
- Sentinel Lymph Node Biopsy/economics
Collapse
Affiliation(s)
- Peter Schrenk
- Second Department of Surgery-Ludwig Boltzmann Institute for Surgical Endoscopy, AKH Linz, Linz, Austria.
| | | | | | | | | | | |
Collapse
|
35
|
Knauer M, Konstantiniuk P, Haid A, Wenzl E, Riegler-Keil M, Pöstlberger S, Reitsamer R, Schrenk P. Multicentric Breast Cancer: A New Indication for Sentinel Node Biopsy—A Multi-Institutional Validation Study. J Clin Oncol 2006; 24:3374-80. [PMID: 16849751 DOI: 10.1200/jco.2006.05.7372] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Purpose Multicentric breast cancer has been considered to be a contraindication for sentinel node (SN) biopsy (SNB). In this prospective multi-institutional trial, SNB-feasibility and accuracy was evaluated in 142 patients with multicentric cancer from the Austrian Sentinel Node Study Group (ASNSG) and compared with data from 3,216 patients with unicentric cancer. Patients and Methods Between 1996 and 2004, 3,730 patients underwent SNB at 15 ASNSG-affiliated hospitals. Patient data were entered in a multicenter database. One hundred forty-two patients presented with multicentric invasive breast cancer and underwent SNB. Results Intraoperatively, a mean number of 1.67 SNs were excised (identification-rate, 91.5%). The incidence of SN metastases was 60.8% (79 of 130). This was confirmed by axillary lymph node dissection (ALND) in 125 patients. Of patients with positive SNs, 60.8% (48 of 79) showed involvement of nonsentinel nodes (NSNs), as did three patients with negative SNs (false-negative rate, 4.0). Sensitivity, negative predictive value, and overall accuracy were 96.0%, 93.3%, and 97.3%, respectively. Ninety-one percent of the patients underwent mastectomy, and 9% were treated with breast conserving surgery. None of the patients have shown axillary recurrence so far (mean follow-up, 28.8 months). Compared with 3,216 patients with unicentric cancer, there was a significantly higher rate of SN metastases as well as in NSNs, whereas there was no difference in detection and false-negative rates. Conclusion Multicentric breast cancer is a new indication for SNB without routine ALND in controlled trials. Given adequate quality control and an interdisciplinary teamwork of surgical, nuclear medicine, and pathology units, SNB is both feasible and accurate in this disease entity.
Collapse
Affiliation(s)
- Michael Knauer
- Department of Surgery, General Hospital, Feldkirch, Austria.
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Knauer M, Konstantiniuk, Haid A, Riegler-Kiel M, Janauer M, Reitsamer R, Köberle-Wührer R, Schrenk P. Multicentric breast cancer as a new indication for sentinel node biopsy — a multiinstitutional validation study. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)80141-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
37
|
Denison U, Konstatiniuk P, Peters-Engl C, Schrenk P, Woelff S, Roka S, Riedl O, Poestlberger S, Hecke D, Haid A. Recurrences and survival after sentinel node biopsy with mandatory axillary node dissection versus sentinel node biopsy followed by axillary node dissection only for positive sentinel nodes — a retrospective analysis of 3159 cases from the Austrian Sentinel Node Study Group. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)80254-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
38
|
Schrenk P, Woelfl S, Bogner S, Moser F, Wayand W. The Use of Sentinel Node Biopsy in Breast Cancer Patients Undergoing Skin Sparing Mastectomy and Immediate Autologous Reconstruction. Plast Reconstr Surg 2005; 116:1278-86. [PMID: 16217468 DOI: 10.1097/01.prs.0000181515.11529.9a] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND Intraoperative frozen section examination of the sentinel node in breast cancer patients is associated with a high number of incorrect negative results with the sentinel node becoming positive in the permanent examination and necessitating a secondary axillary lymph node dissection. A reoperation of the axilla following skin-sparing mastectomy and immediate autologous tissue reconstruction may compromise the vascular pedicle of the flap and should be avoided. METHODS Eighty breast cancer patients underwent skin-sparing mastectomy with immediate autologous reconstruction and sentinel node biopsy followed by axillary lymph node dissection irrespective of the result of the frozen section of the sentinel node. The goal of the study was to identify a subgroup of patients with incorrect negative sentinel node(s) in the frozen section who may forego a secondary axillary lymph node dissection due to a low risk of positive nonsentinel nodes. RESULTS Frozen section examination of the sentinel node was negative in 58 patients and positive in 22 patients. Permanent histologic examination revealed tumor in 13 of 58 (22.4 percent) sentinel node(s) found negative in the frozen section. None of these 13 patients showed positive nodes in the axillary specimen, whereas nine of 22 patients with their metastases in the sentinel node found through intraoperative frozen section examination had additional positive nonsentinel node(s) (p = 0.001). CONCLUSIONS Patients with incorrect negative sentinel node(s) found in the frozen section examination had a significantly decreased risk for additional positive nonsentinel node(s) compared with patients with sentinel node metastases found in the frozen section. However, to avoid a secondary axillary lymph node dissection, the authors suggest performing sentinel node biopsy before mastectomy under local anesthesia to have the permanent result of the sentinel node available before a planned reconstruction.
Collapse
Affiliation(s)
- Peter Schrenk
- Second Department of Surgery, Ludwig Boltzmann Institute for Surgical Laparoscopy, Linz, Austria.
| | | | | | | | | |
Collapse
|
39
|
Schrenk P, Konstantiniuk P, Wölfl S, Bogner S, Roka S, Pöstlberger S, Selim U, Urbania A, Gebhard B, Rudas M, Tausch C. Intraoperative frozen section examination of the sentinel lymph node in breast cancer. Rozhl Chir 2005; 84:217-22. [PMID: 16045116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
AIM OF THE STUDY Intraoperative frozen section (FS) examination of the Sentinel node (SN) in breast cancer patients is questioned due to the relatively high number of positive SN(s) found in the permanent histological examination. This study reviews the data of the Austrian sentinel node study group on FS examination of the SN and tries to identify patients with a high risk of incorrect negative results. METHODS 2326 breast cancer patients of the Austrian Sentinel node study group who underwent SN biopsy and intraoperative FS examination of the SN were further analysed for incorrect negative results and clinicopathologic factors indicating a higher rate of incorrect negative results. RESULTS The FS of the SN was positive in 513 of 2326 patients (22.1%) and negative in 1813 of 2326 patients (77.9%). Permanent histological examination revealed a metastatic SN in 282 of 1813 patients. (incorrect negative rate 15.6%). 158 of 282 patients (56%) were found through H&E serial sectioning, whereas 124 of 282 patients (44%) were only seen in immunohistochemistry. Micrometastases, lobular histology and preoperative chemotherapy were associated with a higher rate of incorrect negative results. CONCLUSION Incorrect negative results of FS examination are seen in 15% of patients and require a secondary axillary lymph node dissection. The disadvantage of missing a positive SN through FS is by far outweighed by the advantage of a single stage operation in case of a positive SN.
Collapse
Affiliation(s)
- P Schrenk
- Second Department of Surgery - Ludwig Boltzmann Institute for Surgical Laparoscopy, Allgemein Offentliches Krankenhaus Linz, Austria.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Schrenk P, Konstantiniuk P, Wölfl S, Bogner S, Haid A, Nemes C, Jagoutz-Herzlinger M, Redtenbacher S. Prediction of non-sentinel lymph node status in breast cancer with a micrometastatic sentinel node. Br J Surg 2005; 92:707-13. [DOI: 10.1002/bjs.4937] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Abstract
Background
Axillary lymph node dissection (ALND) may not be necessary in women with breast cancer who have micrometastasis in a sentinel node (SN), owing to the low risk of non-SN (NSN) involvement. The aim of this study was to identify a subgroup of women with a micrometastatic SN and a negligible risk of positive NSNs in whom ALND may be avoided.
Methods
Some 237 of 241 women with a macrometastatic SN and 122 of 138 with a micrometastatic SN underwent completion ALND and were compared with respect to NSN involvement. The 122 patients with SN micrometastasis were further analysed to determine factors that could predict the risk of positive NSNs.
Results
A total of 121 (51·1 per cent) of 237 women with SN macrometastasis had positive NSNs compared with 22 (18·0 per cent) of 122 with SN micrometastasis (P < 0·001). Multivariate analysis showed that size of SN micrometastasis (odds ratio 3·49 (95 per cent confidence interval (c.i.) 1·32 to 9·23); P = 0·012) and presence of lymphovascular invasion (odds ratio 0·23 (95 per cent c.i. 0·05 to 1·00); P = 0·050) were significantly associated with positive NSNs. SN micrometastasis less than 0·5 mm in diameter combined with absence of lymphovascular invasion was associated with an 8·5 per cent risk of NSN involvement.
Conclusion
Size of micrometastasis and presence of lymphovascular invasion were significantly related to the risk of finding additional positive axillary lymph nodes when the SN contained only micrometastasis.
Collapse
Affiliation(s)
- P Schrenk
- Second Department of Surgery, Ludwig Boltzmann Institute for Surgical Laparoscopy, Linz, Austria
| | - P Konstantiniuk
- Second Department of Surgery, Landeskrankenhaus Graz, Graz, Austria
| | - S Wölfl
- Department of Pathology, Allgemein Offentliches Krankenhaus Linz, Linz, Austria
| | - S Bogner
- Department of Pathology, Allgemein Offentliches Krankenhaus Linz, Linz, Austria
| | - A Haid
- Department of Surgery, Krankenhaus Lainz, Vienna, Austria
| | - C Nemes
- Department of Pathology, Landeskrankenhaus Feldkirch, Feldkirch, Austria
| | | | - S Redtenbacher
- Department of Pathology, Krankenhaus Lainz, Vienna, Austria
| |
Collapse
|
41
|
Peters-Engl C, Konstantiniuk P, Tausch C, Haid A, Hoffmann B, Jagoutz-Herzlinger M, Kugler F, Redtenbacher S, Roka S, Schrenk P, Steinmassl D. The impact of preoperative breast biopsy on the risk of sentinel lymph node metastases: analysis of 2502 cases from the Austrian Sentinel Node Biopsy Study Group. Br J Cancer 2004; 91:1782-6. [PMID: 15477859 PMCID: PMC2410051 DOI: 10.1038/sj.bjc.6602205] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
Preoperative breast biopsy might cause disaggregation of tumour cells and tumour cell spread. The purpose of this study was to investigate the impact of preoperative biopsy on the rate of metastases to the sentinel lymph node (SLN) of patients with primary breast cancer. We report the results of 2502 patients with primary breast cancer, who were operated, and a sentinel node biopsy was performed. The association of preoperative biopsy with the risk of SLN metastases was examined by regression analyses and tested for possible confounding well-known factors for axillary node metastases. In all, 1890 patients were available for final analyses; 1048 (55.4%) patients had a preoperative diagnosis performed by fine-needle aspiration or core biopsy; 641 (33.9%) patients had a positive SLN when conventional H&E and IHC staining was performed. Patients with preoperative breast biopsy showed a 1.37 times (95% CI, 1.13-1.66) increased risk of SLN metastases on univariate analysis, but this result was not persistent when analysis was adjusted for other relevant factors for axillary node metastases, OR 1.09 (95% CI, 0.85-1.40). In addition, subgroup analyses of the risk for occult micro metastases to the SLN (detected by IHC only) on H&E-negative cases also showed no increased risk associated with preoperative biopsy, OR 1.07 (95% CI, 0.69-1.65). The conclusion, based on the present data, is that preoperative breast biopsy does not cause artificial tumour cell spread to the SLN, with possible negative impact on the prognosis of breast cancer.
Collapse
Affiliation(s)
- C Peters-Engl
- Department of Gynaecology and Obstetrics, Krankenhaus Lainz, Wolkersbergenstrasse 1, A-1130 Vienna, Austria.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Peters-Engl C, Konstantiniuk P, Tausch C, Haid A, Hoffmann B, Jagoutz-Herzlinger M, Kugler F, Redtenbacher S, Roka S, Schrenk P. The impact of preoperative breast biopsy on the risk of sentinel lymph node metastases: analysis of 2502 cases from the Austrian Sentinel Node Biopsy Study Group. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.562] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Peters-Engl
- KH Lainz, Vienna, Austria; Department of Vascular Surgery, University of Graz, Austria; Department of Surgery, Barmherzige Schwestern Hospital Linz, Austria; Department of Surgery, Landeskrankenhaus Feldirch, Austria; 2nd Department of Surgery, Wilhelminenspital Vienna, Austria; Department of Pathology, KH Lainz Vienna, Austria; Department of General Surgery, University of Vienna, Austria; 2nd Department of Surgery, AKH Linz, Austria
| | - P. Konstantiniuk
- KH Lainz, Vienna, Austria; Department of Vascular Surgery, University of Graz, Austria; Department of Surgery, Barmherzige Schwestern Hospital Linz, Austria; Department of Surgery, Landeskrankenhaus Feldirch, Austria; 2nd Department of Surgery, Wilhelminenspital Vienna, Austria; Department of Pathology, KH Lainz Vienna, Austria; Department of General Surgery, University of Vienna, Austria; 2nd Department of Surgery, AKH Linz, Austria
| | - C. Tausch
- KH Lainz, Vienna, Austria; Department of Vascular Surgery, University of Graz, Austria; Department of Surgery, Barmherzige Schwestern Hospital Linz, Austria; Department of Surgery, Landeskrankenhaus Feldirch, Austria; 2nd Department of Surgery, Wilhelminenspital Vienna, Austria; Department of Pathology, KH Lainz Vienna, Austria; Department of General Surgery, University of Vienna, Austria; 2nd Department of Surgery, AKH Linz, Austria
| | - A. Haid
- KH Lainz, Vienna, Austria; Department of Vascular Surgery, University of Graz, Austria; Department of Surgery, Barmherzige Schwestern Hospital Linz, Austria; Department of Surgery, Landeskrankenhaus Feldirch, Austria; 2nd Department of Surgery, Wilhelminenspital Vienna, Austria; Department of Pathology, KH Lainz Vienna, Austria; Department of General Surgery, University of Vienna, Austria; 2nd Department of Surgery, AKH Linz, Austria
| | - B. Hoffmann
- KH Lainz, Vienna, Austria; Department of Vascular Surgery, University of Graz, Austria; Department of Surgery, Barmherzige Schwestern Hospital Linz, Austria; Department of Surgery, Landeskrankenhaus Feldirch, Austria; 2nd Department of Surgery, Wilhelminenspital Vienna, Austria; Department of Pathology, KH Lainz Vienna, Austria; Department of General Surgery, University of Vienna, Austria; 2nd Department of Surgery, AKH Linz, Austria
| | - M. Jagoutz-Herzlinger
- KH Lainz, Vienna, Austria; Department of Vascular Surgery, University of Graz, Austria; Department of Surgery, Barmherzige Schwestern Hospital Linz, Austria; Department of Surgery, Landeskrankenhaus Feldirch, Austria; 2nd Department of Surgery, Wilhelminenspital Vienna, Austria; Department of Pathology, KH Lainz Vienna, Austria; Department of General Surgery, University of Vienna, Austria; 2nd Department of Surgery, AKH Linz, Austria
| | - F. Kugler
- KH Lainz, Vienna, Austria; Department of Vascular Surgery, University of Graz, Austria; Department of Surgery, Barmherzige Schwestern Hospital Linz, Austria; Department of Surgery, Landeskrankenhaus Feldirch, Austria; 2nd Department of Surgery, Wilhelminenspital Vienna, Austria; Department of Pathology, KH Lainz Vienna, Austria; Department of General Surgery, University of Vienna, Austria; 2nd Department of Surgery, AKH Linz, Austria
| | - S. Redtenbacher
- KH Lainz, Vienna, Austria; Department of Vascular Surgery, University of Graz, Austria; Department of Surgery, Barmherzige Schwestern Hospital Linz, Austria; Department of Surgery, Landeskrankenhaus Feldirch, Austria; 2nd Department of Surgery, Wilhelminenspital Vienna, Austria; Department of Pathology, KH Lainz Vienna, Austria; Department of General Surgery, University of Vienna, Austria; 2nd Department of Surgery, AKH Linz, Austria
| | - S. Roka
- KH Lainz, Vienna, Austria; Department of Vascular Surgery, University of Graz, Austria; Department of Surgery, Barmherzige Schwestern Hospital Linz, Austria; Department of Surgery, Landeskrankenhaus Feldirch, Austria; 2nd Department of Surgery, Wilhelminenspital Vienna, Austria; Department of Pathology, KH Lainz Vienna, Austria; Department of General Surgery, University of Vienna, Austria; 2nd Department of Surgery, AKH Linz, Austria
| | - P. Schrenk
- KH Lainz, Vienna, Austria; Department of Vascular Surgery, University of Graz, Austria; Department of Surgery, Barmherzige Schwestern Hospital Linz, Austria; Department of Surgery, Landeskrankenhaus Feldirch, Austria; 2nd Department of Surgery, Wilhelminenspital Vienna, Austria; Department of Pathology, KH Lainz Vienna, Austria; Department of General Surgery, University of Vienna, Austria; 2nd Department of Surgery, AKH Linz, Austria
| |
Collapse
|
43
|
Shamiyeh A, Vattay P, Tulipan L, Schrenk P, Bogner S, Danis J, Wayand W. Closure of the cystic duct during laparoscopic cholecystectomy with a new feedback-controlled bipolar sealing system in case of biliary obstruction--an experimental study in pigs. Hepatogastroenterology 2004; 51:931-3. [PMID: 15239216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
Abstract
BACKGROUND/AIMS The excellent results of new devices like the new bipolar feedback-controlled sealing system (LigaSure) for closure of blood vessels encouraged surgeons to use these instruments for other structures like bile ducts. The aim of this study was to evaluate the feasibility of closure of cystic duct in case of biliary obstruction. METHODOLOGY Ten domestic pigs underwent laparoscopic cholecystectomy sealing the cystic duct with LigaSure. The common bile duct was closed with an endoclip to create a biliary hypertension. On the 12th postoperative day blood samples were taken for liver enzymes. At autopsy on day 15 the pigs were investigated for bile leaks or biliary peritonitis. The cystic duct was resected for histological examination. RESULTS Seven pigs survived, one pig died during introduction of anesthesia, one on the 1st and one on the 2nd postoperative day without any findings at the autopsy. One pig out of 7 had a bile leak; the other 6 were without any sign of leakage. Histologically 3 pigs had a regular coagulation zone at the cystic duct, 3 had a total necrosis, one a partial necrosis of the mucosa only. CONCLUSIONS Though there was only one insufficiency, the feedback-controlled bipolar vessel sealer cannot be recommended for biliary surgery with regard to the high rate of necrosis stated in our experiment.
Collapse
Affiliation(s)
- A Shamiyeh
- Ludwig Boltzmann Institute for Operative Laparoscopy and 2nd Surgical Department, General hospital Linz, Linz, Austria.
| | | | | | | | | | | | | |
Collapse
|
44
|
Schrenk P, Konstantiniuk P, Wölfl S, Roka S, Pöstlberger S, Haid A, Tausch C, Jagoutz-Herzlinger M, Rudas M. Non-Sentinel lymph node involvement in breast cancer patients with a micrometastatic sentinel lymph node: Results of the Austrian Sentinel Node Study Group. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)90678-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
45
|
Schrenk P, Moser F, Wölfl S, Bogner S, Fridrik M, Gitter T, Hochreiner G, Wayand W. Use of reduction mammoplasty techniques in breast cancer conservation therapy. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)90977-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
46
|
Abstract
Sentinel node (SN) biopsy in breast cancer patients following preoperative chemotherapy is associated with a decreased identification rate and an increased false-negative rate when compared to SN biopsy performed in untreated patients. We performed SN biopsy in 21 breast cancer patients scheduled for preoperative chemotherapy using either vital blue dye alone (n = 11) or in combination with a radiocolloid (n = 10). Following a mean of four cycles of preoperative chemotherapy, surgery to the breast and complete axillary lymph node dissection was performed irrespective of the SN status. A mean of 1.9 SNs were identified in all 21 patients, 12 were SN negative and 9 were SN positive. Preoperative chemotherapy decreased mean tumor size from 40.2 to 17.7 mm and breast conservation was possible in 14 of 21 patients (67%). All SN-negative patients and three of nine SN-positive patients had negative lymph nodes in the axillary specimen, whereas six of nine patients with a positive SN revealed lymph node metastases following preoperative chemotherapy. SN biopsy performed before preoperative chemotherapy found a 100% identification rate with no false-negative results. Following preoperative chemotherapy, SN-negative patients may forego a complete axillary dissection.
Collapse
Affiliation(s)
- Peter Schrenk
- Second Department of Surgery-Ludwig Boltzmann Institute, Allgemein Offentliches Krankenhaus, Linz, Austria.
| | | | | | | |
Collapse
|
47
|
Abstract
BACKGROUND Transilluminated powered phlebectomy is a new procedure for minimal invasive varicose vein surgery. OBJECTIVE To evaluate this technique for its benefit and the technique-related risks and complications. METHODS Thirty patients were prospectively operated with this new technique by the same surgeon (11 of them bilaterally [41 legs in all]). According to the sonography, sapheno-femoral-junction ligation and stripping of the long saphenous vein were done if necessary. The phlebectomy of the side branches was done with the new system (Trivex System/Smith and Nephew). The postoperative follow-up was at 10 days and 6 weeks. RESULTS There was no intraoperative complication. The mean operation time per leg was 40 minutes. Twenty-five patients had an uneventful postoperative course. Twenty two have been very satisfied with the cosmetically result. Two patients required reoperation because of postoperative hematoma. One patient developed a seroma, which could be managed via puncture. One patient developed persistent brown scar. The overall morbidity was 12.2%. CONCLUSION Using transilluminated powered phlebectomy, multiple and large incisions could be reduced. A perfect cosmetic outcome might be reached if the surgeon is aware of technique-related complications. To evaluate the real value of this technique, further randomized trials are necessary.
Collapse
Affiliation(s)
- Andreas Shamiyeh
- Ludwig Boltzmann Institute for Operative Laparoscopy at the Second Surgical Department, Academic Teaching Hospital, Linz, Austria.
| | | | | | | | | |
Collapse
|
48
|
Shamiyeh A, Schrenk P, Wayand WU. Prospective trial comparing bilateral and unilateral varicose vein surgery. Langenbecks Arch Surg 2003; 387:402-5. [PMID: 12607119 DOI: 10.1007/s00423-002-0347-1] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2002] [Accepted: 12/03/2002] [Indexed: 10/25/2022]
Abstract
BACKGROUND This study compared bilateral and unilateral varicose vein surgery in primary varicosis of the long or short saphenous vein with respect to blood loss. PATIENTS AND METHODS The prospective trial assessed postoperative pain, analgesic consumption, blood loss, return to physical activity and work, cosmetic result, complications, hospitalization, patient satisfaction, and hospital cost in 73 consecutive patients undergoing unilateral ( n=40) or bilateral ( n=33) varicose vein surgery. RESULTS There were no statistically significant differences between the two groups in postoperative pain, postoperative analgesic consumption immediately postoperatively and after 8 h, median postoperative stay, return to work and physical activity, or cosmetic result. All patients but one were either satisfied or very satisfied 6 weeks postoperatively. CONCLUSIONS Patients undergoing a bilateral stripping operation did not differ from those undergoing unilateral operation. Therefore we recommend bilateral operation when indicated.
Collapse
Affiliation(s)
- Andreas Shamiyeh
- Second Surgical Department, Ludwig Boltzmann Institute for Operative Laparoscopy, General Hospital, 4020, Linz, Austria.
| | | | | |
Collapse
|
49
|
Schrenk P, Wolfl S, Tausch C, Mauritz C, Konstantiniuk P, Haid A, Riegler-Keil M, Rudas M. Sentinel Node Biopsy in Patients with Multicentric Breast Cancer using a Subareolar Injection Technique. Eur Surg 2002. [DOI: 10.1046/j.1563-2563.2002.02069.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
50
|
Pichler-Gebhard B, Konstantiniuk P, Tausch C, Joerg L, Haid A, Schrenk P, Peters-Engl C, Roka S. Factors Affecting Identification Rate and Positivity of the Sentinel Node in Breast Cancer in 1567 Patients, Using Blue Dye and 99 mTc-Labelled Colloid, Based on a Multicentre Database Project in Austria. Eur Surg 2002. [DOI: 10.1046/j.1563-2563.2002.02066.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|